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Abstract 
Tau is a microtubule-associated protein that is typically found in the axons of neurons.  Six 
isoforms of the protein can be generated through alternative mRNA splicing and all are found in 
the adult brain.  The protein is closely associated with a group of neurodegenerative diseases, 
including Alzheimer’s disease, collectively known as tauopathies.  In these diseases tau 
dissociates from microtubules and begins to polymerize into aggregates that are typically 
fibrillary in nature.  The deposition of these aggregates is closely linked to the death and 
dysfunction of neurons and eventually leads to atrophy of specific regions of the brain.  
Tauopathies display a wide variety of pathologies that distinguish them from each other, 
including aggregate morphology and isoform inclusion.  Differential conformational changes in 
pathological forms of the protein may affect its propensity for aggregation and function.  
Hyperphosphorylation of tau or inherited mutations, known as FTDP-17 mutations, may induce 
these conformational changes and alter aggregation and function. The studies described here 
used in vitro assays to determine how hyperphosphorylation affects each of the tau isoforms and 
how various FTDP-17 mutations can alter aggregation and function.  This information helps to 
describe how intrinsic differences due to modifications of tau can manifest themselves in the 
varying pathologies of tauopathies.  This can be applied to C. elegans models of tauopathies to 
determine the effects in living neurons.  The results demonstrate that similar phosphorylation 
patterns in tau can result in very different effects on the protein’s aggregation and ability to 
stabilize microtubule polymerization depending on the isoform background.  This suggests that 
phosphorylation pattern is sufficient to induce differential aggregation and may affect the 
morphology and isoform contents of aggregates. Similarly, FTDP-17 mutations also induced 
very different effects on tau aggregation and function.  This indicates that these mutations may 
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be affecting disease pathologies in very different manners.  Differences between tau isoforms 
and FTDP-17 mutations are likely affecting the phenotypes seen in animal models of disease and 
should not be ignored.  This is being tested by developing several unique C. elegans models of 
tauopathies. 
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Chapter I Introduction 
1.1 Tau Introduction 
The tau protein was initially discovered in 1975 and noted for its ability to stabilize the assembly 
of tubulin into microtubules (1).  Researchers continued to study the biochemical and functional 
properties of the protein over the next several years with most of the effort focusing on its 
relationships with microtubules (2).  However, tau took on added importance in the mid-1980’s 
when it was found to be the major component of intracellular neurofibrillary tangles, inclusions 
associated with Alzheimer’s disease (AD) and first described in 1907 by Alois Alzheimer (3-5).  
Fibrillary inclusions primarily made up of aggregated tau were also found to be present in many 
other neurodegenerative disorders, collectively known as tauopathies (6, 7).  The abnormal 
aggregation of the tau protein is found in all tauopathies and is also closely associated with 
neurodegeneration of certain regions of the brain (reviewed in (8)).  In the nearly three decades 
since the protein was first linked with neurodegenerative disorders, scientists have learned more 
about the functions of tau and how its aggregation may be toxic to neurons.  Despite this 
progress there are still significant gaps in our understanding of why tau begins to aggregate, how 
this aggregation may be exerting toxic effects, and how these aspects can be targeted by effective 
treatments.  
 
The human tau gene is primarily expressed in the neurons of the central nervous system and the 
protein itself typically localizes to the axons of the neurons but can be found in the 
somatodendritic compartment as well (9-11).  The gene is located on chromosome 17 and made 
up of 16 exons (12, 13).  Alternative mRNA splicing is used to generate the six isoforms of tau 
that are found in the human brain (Figure 1.1) (14).  These isoforms utilize 11 of the exons  
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Figure 1.1 
 
Figure 1.1 Tau isoforms with microtubule-binding repeats.  In the human brain six tau 
isoforms are generated through alternative mRNA splicing of exons 2, 3, and 10 and range from 
352 to 441 amino acids in length.  Exon 10 contains the 2
nd
 of four microtubule-binding repeat 
regions (MTBR).  The nomenclature refers to the number of N-terminal exons (0N, 1N, or 2N) 
and the number of MTBR (3R or 4R) present in the isoform.   
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present in the tau gene and differ based on their inclusion of the 2
nd
, 3
rd
, and 10
th
 exons.  The 
nomenclature used to define these isoforms describes the presence or absence of exons 2 and 3, 
the N-terminal exons, as 0N, 1N, or 2N.  The splicing of exon 3 depends on the presence of exon 
2 and it is never included without the 2
nd
 exon (15).  The absence or presence of exon 10 is noted 
as 3R or 4R respectively due to that exon containing one of the four potential microtubule-
binding repeat domains (MTBR).  While the developing fetal brain only contains 0N3R tau, the 
adult brain expresses all six isoforms (16).  The 3R to 4R ratio is approximately 1:1 while the 
breakdown of N-terminal exon inclusion is approximately 9% 2N, 54% 1N, and 37% 0N (17, 
18).   
 
Differences between the tau isoforms likely affect some of the protein’s major functions of 
stabilizing and promoting the assembly of microtubules (1, 19).  As mentioned above, the 
isoform nomenclature includes 3R or 4R depending on the number of MTBR present in the 
protein.  These regions measure 31-32 amino acids in length and contain an 18-residue imperfect 
repeat followed by a 13 or 14 residue inter-repeat region (Figure 1.2) (20).  The repeat and the 
inter-repeat regions are both involved in binding to microtubules but other sequences around the 
MTBR affect the interactions as well (21, 22).  Each MTBR contains a conserved PGGG 
sequence that may form part of a β-turn motif that forms a loop upon binding to microtubules 
(23).  Individually, each MTBR is able to bind microtubules relatively weakly, but, there appears 
to be a cooperative binding effect among the MTBR and the adjoining regions (24, 25).  Due to 
the presence of MTBR2, the 4R isoforms bind more tightly than 3R isoforms and promote the 
assembly of microtubules more efficiently (18, 26).  Upon binding, the N-terminal portion of the  
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Figure 1.2 
 
Figure 1.2 Sequence of Tau Microtubule-Binding Repeat Region.  The amino acid sequence 
of the region including and surrounding the microtubule-binding repeat region (MTBR) of tau is 
displayed here.  The amino acids left of the vertical line represent the repeat regions while those 
to the right of the line include the inter-repeat regions between the repeats as well as amino acids 
before and after the MTBR.  The amino acids in gray represent those included in exon 10, 
subject to alternative mRNA splicing.  They are included in the 4R isoforms and excluded in 3R 
isoforms.  
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protein remains unbound and is referred to as the “projection domain” (27).  In vitro binding is 
saturated at a 2:1 tubulin to tau ratio, but, in neurons, tubulin is found at 20-40 μM  
concentrations while tau is typically found at ~1 μM (19, 24, 28, 29).  Tau has demonstrated the 
ability to bind to the inside as well as the outside of microtubules (23, 30). 
 
1.2 Tau function 
The primary functions of tau seem to involve these direct interactions with microtubules.  Tau 
has the ability to promote microtubule nucleation as well as their stabilization by inhibiting the 
dynamic instability (1, 31-33).  Given the importance of microtubules in maintaining the shapes 
of projections it is not surprising that removal of tau prevents neurite growth (34).  In addition to 
stabilization, tau also affects microtubule bundling and spacing, a process that is affected by the 
sizes of the tau isoform (35-37).  The bundling may be important for maintaining axonal 
structure as well the transport of cellular cargo throughout the axon. 
 
The transport of proteins and other cargo is particularly important for neurons due to the 
distances between the cell body and the tip of the axon and is carried out through the use of 
kinesin and dynein, motor proteins that pull the cargo along microtubules.  Overexpression of tau 
inhibits the transport of cargo along microtubules, a process that occurs in an MTBR-dependent 
manner (38, 39).  Tau may be inhibiting axonal transport by competitively binding to 
microtubules in place of motor proteins but this behavior has not been replicated in actual axons 
and at physiological conditions (40, 41). 
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In addition to the direct binding of microtubules, tau interacts with several other cellular 
components that may be related to other important tau functions.  The protein’s “projection 
domain” interacts with the plasma membrane and may be involved in anchoring the protein (42).  
Tau appears to be involved in remodeling of the actin cytoskeleton and may assist in mediating 
microtubule-actin interactions (43-45).  Interactions between tau and other proteins may affect 
the functions of tau and the other protein itself.  Included in these interacting partners are several 
kinases, phosphatases, and chaperone proteins.  Tau can bind to several members of the src 
family, fyn being among the most characterized, and affect the localization of those kinases as 
well (46, 47).  Tau also interacts with phosphatases, such as PP2A (48).  Approximately 1 in 5 
amino acids in tau is a potential phosphorylation site and the level and pattern of phosphorylation 
may have a large impact on its function.  Phosphorylation and tau will be discussed in more 
detail below.  Finally, the binding of certain chaperone proteins may affect the functions of tau 
and reduce its pathological aggregation (49). 
 
1.3 Tau structure and domains 
The fairly large number of binding partners for tau is partially due to some unique characteristics 
of the protein.  Tau has been described as a “natively unfolded” protein due to its highly flexible 
nature and the lack of identifiable secondary and tertiary structures (50, 51).  The protein is 
extremely hydrophilic and, in a normal state, will remain soluble at relatively high 
concentrations.  The hydrophilic nature of the protein is due to the high number of polar amino 
acids, like serine and threonine, as well as the number of charged amino acids.  Despite a net 
charge of only +2, the full-length tau isoform is made up of more than 25% charged amino acids. 
The highly flexible structure of tau allows it to promiscuously bind to other proteins and even 
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harsh treatments with heat and other denaturing agents do not have major effects on the ability of 
the protein to perform its normal functions (52).  Despite this flexibility, there is some detectable 
secondary structure that is of particular importance for tau.  Through nuclear magnetic resonance 
and other techniques, some of this secondary structure has been determined (Figure 1.3) (51).  Of 
particular importance are β-strands that are found within the MTBR and which may be more 
prevalent when the protein is bound to microtubules (53).  In addition to the secondary structures 
evidence suggests that higher order structure exists as well.  The protein exists in what has been 
described as a “paperclip” or “global hairpin” conformation where the N- and C-terminal ends of 
the protein fold over to interact with each other and the interior domains of the protein (54, 55). 
 
Included in these interior domains are the three or four MTBR, discussed earlier, and two 
proline-rich domains just upstream of them.  The proline-rich region is contained between amino 
acids 150-240.  Many of the prolines in this region are next to serines or threonines making them 
targets of proline-directed kinases.  Additionally, other prolines are found in PXXP motifs that 
can bind to the SH3 domains of src-family kinases and other proteins (46).  The proline-rich 
region is considered separate from the MTBR even though microtubule-binding interactions can 
be detected from amino acids 200 through 400 (53, 56).  The “projection domain” refers to the 
N-terminal region of the protein because it projects from the microtubules when tau is bound to 
them (27, 57).  This domain contains a higher proportion of acidic amino acids while the MTBR 
is more basic in nature, which likely assists in the binding to the acidic C-terminal ends of 
tubulin subunits (58). 
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Figure 1.3 
 
Figure 1.3 Global hairpin conformation of tau and its known secondary structure.  The N- 
and C-terminal ends of tau interact with each other as well as the interior of the protein in a 
conformation that has been described as the “global hairpin.”  The tau protein is highly flexible 
and largely unstructured but NMR studies have determined that regions of transient secondary 
structure do exist.  The β-strands are represented by arrows and α-helices are represented by 
cylinders. 
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While the evidence suggests several different functions for tau, mice lacking the tau gene 
initially seemed to suffer few observable defects outside of minor alterations in microtubule 
patterning (59).  However, more recent studies have indicated some behavioral changes and 
brain atrophy occur in aged tau-knockout mice (60, 61).  Despite the seeming lack of evidence  
for essential functions of the protein, tau has retained the focus of investigators for many years 
due to its obvious dysfunction in tauopathies. 
 
1.4 Tauopathies 
Tauopathies are a group of disorders characterized by an abnormal intracellular aggregation of 
the tau protein that is closely associated temporally and spatially with the degeneration and death 
of neurons in the brain.  While tau aggregation and neuronal dysfunction generally characterize 
tauopathies, their specific pathologies can vary widely from each other.  These differences 
manifest themselves in the morphologies of aggregates associated with the diseases, the locations 
and cell-types displaying the pathologies, and the related symptoms which correlate to the 
functions associated with the particular affected brain regions.  Brief overviews of some of the 
major tauopathies and their pathologies will be discussed below. 
 
1.4.1 Alzheimer’s disease 
The most common and widely-studied tauopathy is Alzheimer’s disease.  The two major 
characteristics of the disease are found in the brain and are intracellular neurofibrillary tangles, 
made up of the tau protein, and extracellular plaques, made up primarily of the β-amyloid (Aβ) 
peptide (62).  The tau tangles can be found before plaques and mirror the loss of neuronal axons 
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and, as the disease progresses, the neurons themselves (63).  The neurofibrillary tangles 
primarily contain hyperphosphorylated tau that has polymerized into paired helical filaments 
(PHF).  The PHF are the predominant structure found in NFT but straight filaments (SF) are 
found as well and the two types of filaments combine to form a pyramidal shaped inclusion (64).  
PHFs appear as two filaments wrapped around each other and display a periodicity of around 80 
nm and variable width (65).  SFs lack periodicity and can also vary in their width (66).  
Aggregates in AD are made up of all 6 tau isoforms in roughly the same percentages as are found 
in a normal brain (67, 68).  The disease is much more common in the elderly and the progression 
of the disease can require decades to reach the final stages (69).  This progression can be 
described in stages based on the location and severity of the protein aggregation pathologies, 
which may be present before external symptoms appear (62).  The initial tau pathology, found in 
projection neurons of the locus coeruleus, is known as the “pretangle phase” because 
hyperphosphorylated and aggregated tau can be detected through immunostaining but has not yet 
progressed to the level of full tangles (reviewed in (70)).  Tangle pathology first develops on the 
entorhinal cortex and spreads to the amygdala and hippocampus before finally forming in all of 
cerebral cortex and parts of the midbrain and thalamus (70).  The outward signs of the disease 
are usually not apparent until the later stages of the progression of tau pathology but are typified 
by dementia, including loss of memory and changes in emotional behavior. 
 
Around 5% of AD cases are associated with a particular genetic polymorphism and typically 
present much earlier than the sporadic cases that have no apparent genetic mutations.  These 
mutations occur in the amyloid precursor protein (APP) gene or 1 of the 2 presenilin genes (71-
73).  APP is the protein product that is cleaved to generate Aβ and presenilins are part of the 
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protease complex that cleaves APP indicating that Aβ pathology may be an initiating factor in 
the disease.  A particular allele of the ApoE gene, associated with lipid metabolism, is also an 
associated risk factor for AD and may play a role in immune function or processing of Aβ. 
 
While tau aggregation and neurodegeneration are closely correlated, the role of the protein’s 
aggregation in the initiation of AD has been a divisive issue in the field.  As mentioned above, 
AD displays aggregation of the tau protein but is also known for the extracellular accumulation 
Aβ (reviewed in (74)).  Crosses of transgenic mice expressing mutant APP gene and a mutated 
tau gene enhanced tau pathology but not Aβ pathology compared to the initial transgenic line 
(75).  This indicated that the presence of Aβ pathology led to tau pathology but not the reverse.  
The mutations in the APP gene can lead to early-onset forms of the disease but there is no 
mutation in tau associated with AD.  These pieces of evidence led many AD researchers to focus 
primarily on Aβ for its roles in disease progression and potential therapeutic intervention but 
evidence supporting a greater role for tau in AD and other neurodegenerative diseases continues 
to mount.   
 
While Aβ pathology may be upstream of tau, the locations of NFT more closely correlates with 
regions of neurodegeneration and the amount of tangles correlates with the levels of dementia 
(76-79).  The discovery of several unique mutations in the tau gene that directly led to early-
onset tauopathies provided evidence that alterations in the gene itself could result in tau 
aggregation and neurodegeneration (80-82).  In addition, Aβ requires the presence of tau in order 
to exert toxic effects and reduction of tau levels decreases the effects on memory in mice (83, 
84).  Meanwhile, tau itself is able to exert toxicity as the overexpression of wild-type tau or 
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aggregate-prone tau constructs can cause toxicity in cultured cells or in various in vivo models 
(85-87).  Finally, many other sporadic tauopathies described below display tau pathology and the 
related neuronal degeneration without any Aβ pathology (8).  For these reasons many believe the 
tau protein to be the key mediator of toxicity in AD.   
 
1.4.2 Pick’s Disease 
Pick’s disease (PiD) is one such disorder that is characterized by aggregation of the tau protein 
but lacks Aβ pathology.  However, instead of NFT, PiD is associated with Pick bodies, spherical 
inclusions primarily made up of tau filaments that are wider than those found in AD but also in 
straight and paired helical forms (88-90).  The aggregates are made up almost exclusively of 3R 
tau isoforms, those lacking exon 10, and tau protein that has not been phosphorylated at S262 
(91, 92).  Different subsets of neurons are vulnerable to tau aggregation in PiD than in AD.  In 
PiD, the frontotemporal lobar and limbic system are greatly affected as well as parts of the 
neocortex and dentate granular cells of the hippocampus (90, 92).  Differences in tau aggregation 
relative to AD may be reflective of alternate initiating factors or symptomatic of the type of 
neurons that are affected.  For example, the dentate granular cells primarily express 3R isoforms 
and may be disproportionately targeted if those isoforms are more likely to aggregate under 
certain conditions (93). 
 
1.4.3 Progressive Supranuclear Palsy 
Progressive supranuclear palsy (PSP) differs from many other tauopathies in that its symptoms 
are primarily characterized by movement defects (94).  In addition to a loss of balance, eye 
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movement, and ability to swallow, the disease is associated with personality changes.  The 
neuropathology displays the loss of neurons in the basal ganglia, subthalamus, and brainstem 
regions but not in the frontal cortex as in AD (95).  This neuronal loss is associated with NFTs 
that are more globular in nature than those associated with AD and primarily formed from 
straight filaments that are narrower than PHFs (7, 96, 97).  The tau found in the filaments is 
hyperphosphorylated and primarily 4R isoforms (98, 99).  Increases in the levels of 4R tau 
mRNA in the brainstem of PSP-affected brains could help explain the preferential aggregation of 
that isoform (100). 
 
1.4.4 Corticobasal Degeneration 
Corticobasal degeneration (CBD) is a disease that is similar to PSP in many respects.  The tau 
aggregates isolated from CBD brains are primarily made up of 4R isoforms that include 1 or both 
of the N-terminal exons that can be present (99, 101).  However, CBD pathology is found in the 
cerebral cortex, cerebellum, and substantia nigra (102).  The aggregates are similar to PHFs and 
SFs and combine to form fibrillary inclusions as well as neuropil threads, tau immunoreactive 
groups of fibrils associated with neurite projections (6, 101). 
 
1.4.5 Chronic Traumatic Encephalopathy 
Chronic traumatic encephalopathy (CTE) has recently entered the public consciousness due to 
revelations about its prevalence in military veterans and athletes who have been subjected to 
repeated brain traumas (103).  The disease is characterized by severe atrophy of the frontal and 
temporal cortices, medial temporal lobe, and hippocampus, among other regions (103, 104).  
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Symptoms can include dementia, personality changes, and motor defects resembling Parkinson’s 
disease (105).  The tau pathology organized into variably shaped NFTs and neuritic threads 
while amyloid plaques were rare but occasionally present (106).  
 
1.4.6 Frontotemporal Dementia with Parkinsonism Linked to Chromosome 17 
The Frontotemporal Dementia with Parkinsonism Linked to Chromosome 17 (FTDP-17) 
disorders are actually a collection of tauopathies with overlapping phenotypes and a root cause 
tied to autosomal dominant mutations.  This group of diseases has been subject to a complex and 
occasionally confusing nomenclature but, here, the FTDP-17 term will refer only to diseases 
associated with mutations in the tau gene itself.  The discovery of several of these mutations in 
the late 1990’s provided much support to the hypothesis that tau aggregation could itself be toxic 
to neurons (80, 107, 108).  To date there are 31 known missense mutations and 10 silent 
mutations in the tau gene that are associated with early-onset tauopathies (Table 1.1).  The 
aggregation of tau is prevalent in the brains of those affected by these diseases but the pathology 
can be highly variable between mutations and even, in some cases, among individuals with the 
same mutation.  The tau pathology can be found in differing neuronal types as well as glial cells, 
can vary morphologically, and can display altered tau isoform expression and aggregation 
(reviewed in (109)).  Due to the varied pathologies, the mutants are often described by their 
similarities to the symptoms and pathologies of AD, PiD, PSP, or CBD.   
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1.5 Tau aggregation 
The presence of tau aggregation in all of these diseases strongly suggests that it may be having a 
toxic effect on neurons but very little is known about the mechanisms of this toxicity or why the 
aggregate morphologies can vary so widely.  One aspect of the debate surrounding tau 
aggregation focuses on the type of tau aggregate that is toxic.  Because the larger NFTs were 
easily identifiable and so closely associated with degeneration of neurons and the onset of 
dementia it was assumed that they must be toxic.  More recent evidence suggests that the smaller 
aggregates, described as oligomers, are more toxic. 
 
In order to understand tau toxicity it is useful to understand what is known about the aggregation 
of the protein.  Tau monomers interact with each other through 2 hexapeptide motifs that take the 
form of β-strands that can polymerize through the formation of cross-β structure (110-112).  The 
first sequence, 
275
VQIINK, is located in the 2
nd
 MTBR which is only found in 4R isoforms while 
the second sequence, 
305
VQIVYK is in the 3
rd
 MTBR.  The sequences form intermolecular cross-
β structure that make up the core of the tau fibril but detailed information about this structure 
remains elusive due to the flexible nature of the rest of the protein.  Initially, monomers join 
together in this manner to form oligomers that are still soluble and more prevalent than 
previously thought (113).  This step can be described as a nucleation event while the growth of 
oligomers is an elongation phase.  The oligomers grow into larger, fibrous aggregates by joining 
together or through the addition of more monomeric tau.  Often these aggregates take the form of 
PHF and display a periodicity of around 80 nm in AD (64, 114, 115).  Less common are the SF, 
also found in AD and PiD, that contain some similarities to PHF but lack periodicity (66, 116).  
Both types of filaments have a core, made up of the regions of the protein around the 
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hexapeptide sequences described above, as well as a “fuzzy coat”, made up of the N- and C-
terminal regions of the protein (65, 117).  The fuzzy coat is described as such because its 
flexibility makes it appear fuzzy next to the highly ordered core region (118).  As the fibrils 
accumulate they form larger inclusions bodies that can be observed through direct visualization.  
The inclusions are typically NFT in AD but can vary morphologically in other diseases such as 
Pick bodies in PiD and globose tangles in PSP, (119, 120). 
 
While tau aggregation seems to follow the path of nucleation, elongation, and finally formation 
of large inclusion bodies, information about why the highly soluble protein begins to aggregate 
in the first place is still lacking.  Most of the early research focused on identifying how soluble 
tau differs from insoluble tau.  In this way several key factors were identified and will be 
introduced here.   
 
1.6 Tau phosphorylation 
One difference that may have attracted the most attention is the phosphorylation of tau.  Tau is 
normally phosphorylated at 2 to 3 sites in the normal brain but can have around 5-9 moles of 
phosphate per mole of tau in protein purified from AD brains (121).  This phosphorylation may 
affect the function of the protein (2, 122).  The tau found in PHF and other aggregates associated 
with tauopathies is often found to be hyperphosphorylated (123-126).  Nearly 20% of the 
residues in full-length tau are potential phosphorylation sites and the protein can be 
phosphorylated by a wide range of kinases.  These include proline-directed kinases such as GSK-
3β and cyclin-dependent kinase 5 (cdk5) (127-129).  Both kinases are highly expressed in the 
brain and have been found in conjunction with NFT and affected neurons in AD (130-132).  
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GSK-3β, in particular, phosphorylates tau at a higher level when it is overexpressed in cells and 
mice (133, 134).  Prior phosphorylation by cdk5 increases the amount of tau phosphorylation by 
GSK-3β (128).  Relevant to AD, the presence of Aβ has been demonstrated to promote the 
hyperphosphorylation of tau, possibly through localization or activation of kinases (135, 136). 
 
Much effort has been expended in an attempt to determine how hyperphosphorylation of tau is 
affecting the protein and which sites are of particular importance.  Phosphorylation by GSK-3β 
may lead to increased aggregation of the protein, as demonstrated with in vitro experiments and 
with Drosophilia models (137, 138).  Several of the tau sites phosphorylated by GSK-3β are 
known to be phosphorylated when the protein is found in an aggregated form (128, 139).  All of 
this indicates that phosphorylation by GSK-3β and other kinases may promote the 
polymerization of tau into fibrils.  It is possible that the decreased microtubule-binding ability of 
hyperphosphorylated tau may be increasing the amount of unbound tau until it reaches a critical 
concentration, or the concentration of tau at which aggregation could begin.  Additionally, 
hyperphosphorylation may be affecting the conformation of the protein such that the protein now 
exists in a pro-aggregant state.  These theories are not mutually exclusive.  
 
Phosphorylation of tau at certain sites, such as T231 or S262, inhibits its ability to carry out 
normal microtubule-related functions compared to other forms of the protein and can cause 
nearly all of the phosphorylated protein to dissociate from the microtubules (140-142).  Many 
other sites are phosphorylated early in the course of the disease and lead to dissociation of tau 
from microtubules, including S199, S202, T205, S396, and S404, among others (142-145).  The 
effect seems to be site-specific as phosphorylation at several other GSK-3β-phosphorylated sites 
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seemed to have very little effect on the function of the protein (142).  Tau’s reduced binding 
affinity for microtubules could lead to an increase in the amount of soluble protein inside of the 
neuron.  Unbound and hyperphosphorylated tau may be more likely to aggregate in that state or 
could be further phosphorylated at other sites in order to induce conformational changes that lead 
to tau aggregation.   
 
Studying phosphorylation of a protein, and particularly one with as many potential 
phosphorylation sites as tau, can present certain difficulties.  For example, protein isolated from 
the brain is a heterogeneous mix of phosphorylation levels and phosphorylated sites making it 
difficult to determine which specific factors are of particular importance.  It can also be difficult 
to mimic physiological conditions and control the overall level and specificity of 
phosphorylation during in vitro reactions.  Pseudophosphorylation can be utilized in order to 
address some of these problems.  This technique uses site-directed mutagenesis to alter serine 
and threonine residues, which are both potential phosphorylation sites, into aspartates or 
glutamates.  The bulky and negatively-charged side groups of aspartates and glutamates are 
meant to mimic the effects of phosphorylation at that site.  This technique has been used to 
confirm previous phosphorylation experiments and determine other site-specific effects (146-
148).   
 
Some of these site-specific effects of phosphorylation included decreased microtubule 
interactions as well as an increased propensity for aggregation at certain sites, including at the 
S202, T205, S396, and S404 sites (149-152).  In the brain, these sites were often phosphorylated 
prior to aggregation while other sites, like S422, were phosphorylated later (153).  Interestingly, 
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expression of pseduophosphorylated tau can also be toxic to cultured cells in the absence of tau 
aggregation, indicating that hyperphosphorylated tau may have toxic properties beyond increased 
tau polymerization (154).  Any enhancement or inhibition of tau aggregation due to 
hyperphosphorylation is likely due to conformational changes induced by the post-translational 
modification.  Hyperphosphorylated tau displays an SDS-resistant electrophoretic shift that 
results from an altered conformation and not the incorporation of phosphates (155).  
Pseudophosphorylation of tau, at individual or combinations of several key sites, altered the local 
and long-range intramolecular interactions that make up the global hairpin conformation (156, 
157).  Changing the conformation of tau could make some regions accessible to other tau 
molecules or stabilize secondary structures like the β-strands that are involved in tau-tau binding.   
 
While hyperphosphorylation of tau may be changing the conformation of the protein, it does not 
necessarily mean that it is the causative agent of tau aggregation.  However, tau 
hyperphosphorylation is known to occur prior to aggregation at many key sites and all 
tauopathies are associated with aggregated tau in a hyperphosphorylated state (8, 158).  Some 
phosphorylation patterns seem to enhance tau polymerization in vitro while others may inhibit 
NFT formation and thereby trap tau aggregates in a more toxic oligomeric form (149, 159).  
Previous work in Chris Gamblin’s lab attempted to answer some of the questions about the 
importance of several potential phosphorylation sites by using site-directed mutagenesis to create 
pseudophosphorylation mutants in several different combinations (160).  A combination of 7 
pseudophosphorylation mutations at sites known to be phosphorylated by GSK-3β induced the 
electrophoretic shift associated with pathological tau, decreased interactions with microtubules, 
and, when compared to normal tau in an in vitro polymerization assay, increased filament length 
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but decreased nucleation (160).  Despite a wealth of evidence linking hyperphosphorylation to 
tau aggregation, its exact role remains complex. 
 
1.7 Other tau post-translational modifications 
Tau hyperphosphorylation is the most widely studied of the post-translational modifications and 
seems to have the most robust links to tau dysfunction but the protein also undergoes several 
other alterations that may be affecting its function and aggregation.  These modifications can 
include truncation, ubiquitination, acetylation, glycoslylation, and oxidation.  The effects of 
many of these modifications are still not well-characterized and may have a causative role in tau 
aggregation or merely a byproduct of other factors.  Many of them affect or reflect an inability of 
neurons to properly degrade tau which may lead to increased concentrations of normal or 
modified tau.  One example of this is the several species of truncated tau that can be found in 
NFTs (161).  Some of these truncated forms of tau, such as those with the 20 C-terminal amino 
acid residues removed, can promote aggregation in an in vitro reaction (162, 163).  The presence 
of ubiquitinated tau in NFT could indicate that the protein has been marked for degradation but 
the cell was unable to complete the task due to the protease- and proteasome-resistance of tau 
found in PHFs (164-167).  Another modification of tau that may inhibit its degradation and 
promote aggregation is acetylation, particularly at the K280 residue (168, 169).  Certain patterns 
of glycosylation have also been identified with aggregated tau and may be associated with 
hyperphosphorylation (170).  Finally, oxidation of tau at its two cysteine residues may be leading 
to the formation of inter- or intra-molecular disulfide bonds that could affect the conformation 
and aggregation of the protein (171). 
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1.8 Nucleation of tau aggregation 
Many of these post-translational modifications are associated with aggregated tau in disease-
afflicted brains and affect the in vitro aggregation but cannot be definitively linked to a causal 
role in polymerization.  In vitro aggregation of tau is very difficult to induce without the addition 
of a cofactor and it is possible that one is required in vivo as well.  Typically the cofactors used 
for in vitro experiments are polyanions, free fatty acids, or planar aromatic dyes and include 
heparin (172), arachidonic acid (173), nucleic acids (174), and Congo Red (85).  It is not known 
which cofactors, if any, are important for in vivo tau aggregation but it is possible that tau could 
be interacting with hydrophobic interfaces at the plasma membrane or coming into contact with 
nucleic acids at the ribosome.  Due to its close association with microtubules it may be possible 
that nucleation of tau aggregation is occurring there as well, something that was recently 
demonstrated with taxol-stabilized microtubules (175).  One of the most important recent 
developments in the tau field has been the demonstration that tau aggregates themselves can seed 
the formation of new in vitro and in vivo tau aggregates and the pathology can propagate through 
other synaptically-connected regions of the brain in a self-directed assembly mechanism similar 
to that of the prion protein (176-180). 
 
Due to the difficulties of inducing in vivo and in vitro tau aggregation, FTDP-17 mutations have 
been used in order to enhance this activity.  These variants of tau are associated with early-onset 
dementias and may have intrinsic factors that enhance their polymerization.  Despite the 
unstructured nature of tau, changes to the limited local and global structures of the protein that 
do exist are probable and are likely to affect the aggregation of the protein in direct and indirect 
ways.  Mutations that affect the structure and conformation of tau may enhance phosphorylation, 
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stabilize β-strands important for amyloid formation, expose regions of the protein that may be 
hydrophobic, or inhibit interactions with microtubules. 
 
Most missense mutations are located in one of the four potential MTBR but can also be found at 
the N- or C-termini (Table 1.1, adapted from (181)).  The potential for increased aggregation of 
FTDP-17 mutant forms of tau could be due to an enhanced level of phosphorylation.  However, 
reports on the mutation-specific effects on phosphorylation have been mixed with some 
indications for more or less phosphorylation, even among the same mutations (182, 183).  
Despite the seemingly contradictory results, alterations in phosphorylation patterns far away 
from mutation sites indicate that the mutations are significantly changing the conformation of 
large segments of the protein. 
 
Some FTDP-17 mutations affect the splicing of mRNA, particularly the silent mutations 
(reviewed in (181)).  This imbalance in isoform ratio seems to be sufficient to induce aggregation 
of normal tau.  Some missense mutations also affect splicing ratios while others have no apparent 
effect on mRNA splicing but the aggregated tau can still display altered isoform ratios similar to 
some of the sporadic tauopathies (184, 185).  This indicates there may be mutation-specific 
effects that lead to differential aggregation propensities for individual tau isoforms. 
 
1.9 Animal Models of Tauopathies 
FTDP-17 mutations have frequently been used as enhancers of aggregation in transgenic animal 
models and, through the use of these models, there has been much progress made in 
understanding the role of tau aggregation in the progression of tauopathies.  However, some of 
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these models have, at times, provided contradictory results.  The mechanisms surrounding 
tauopathies appear to be quite complex and seemingly minor variations could result in drastically 
different phenotypes that cloud interpretation of the data.  Many transgenic animal models of 
tauopathies utilize FTDP-17 mutated tau or hyperphosphorylation of tau to induce the protein’s 
aggregation.  Variations in the types of tau expressed could alter morphology within the same 
animal system.  Some of the animal models that have been generated and their morphologies will 
be outlined here. 
 
1.9.1 Mouse models 
Mouse models of tauopathies have the benefits of taking place inside of a complex, mammalian 
brain.  The mouse brain contains endogenous tau that is exclusively made up of 4R isoforms and 
can be left in or knocked out of the transgenic animals.  It is possible for human wild-type tau to 
form aggregates in mice but it requires heavy overexpression and other attempts to generate 
wild-type tau models have not been successful (186).  The addition of a dominant negative form 
of the PP2A phosphatase can also lead to hyperphosphorylation of tau and aggregation (187).  
Because of the difficulties inducing aggregation of endogenous or human wild-type tau, 
modified tau is often used in animal models.  The most common modification is to use an FTDP-
17 mutation.  Transgenic models expressing FTDP-17 versions of tau will typically display 
NFTs that resemble those associated with AD and other tauopathies at lower concentrations that 
wild-type.  The list of FTDP-17 mutations used to induce tau aggregation in mice includes 
G272V, P301L, P301S, V337M, K369I, and R406W (188-192).  Based upon the differences 
associated with human forms of FTDP-17, it is not surprising that the pathologies among these 
mouse models varied as well, with differences arising in the location of tau aggregation and the 
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morphology of aggregates.  Interestingly, these differences may correlate closely with human 
forms of the diseases.  For example, the mice expressing K369I tau replicated several features of 
the PiD-like pathology associated with humans expressing the K369I tau variant as well as 
sporadic human PiD (189).  Models of AD are particularly complicated due to the presence of 
Aβ plaques.  The development of the “triple transgenic” mouse model has recapitulated most 
aspects of the disease by incorporating transgenes that contain mutated versions of presenilin 1, 
APP, and tau (193). 
 
1.9.2 Invertebrate models 
The use of invertebrate models allows the researcher to use a wide variety of genetic tools that 
allow faster and cheaper generation of transgenic models, compared to mice, while still being 
able to model the tauopathies in actual neurons.  The most common invertebrate tauopathy 
model system to date has been in the Drosophila organism.  One of the first Drosophila models 
utilized pan-neuronal expression of the wild-type 0N4R isoform, a model that displayed neuronal 
death with no detectable large aggregates (87).  This lends support to the hypothesis that tau 
toxicity stems from a soluble form of the protein that may be in either a monomeric or 
oligomeric state.  Later studies demonstrated that the tau isoforms had differential effects on 
neurons in the fly brains and that phosphorylation state was also important for toxicity in specific 
subsets of neurons (194, 195).  Most Drosophila models lack fibrillar tau unless it is expressed in 
glial cells indicating that the cellular environment may affect when and how tau aggregates 
(196).  As expected from other models, the addition of FTDP-17 mutations such as R406W 
enhanced toxicity while V337M had minor effects and seemed to ameliorate toxicity (87, 194).  
The totality of work in Drosophila suggests that mutations, phosphorylation patterns, and type of 
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FTDP-17 mutation can induce entirely different effects in the cell types affected and types of 
aggregation. 
 
Somewhat more recently, nematodes have also been used to model tauopathies.  Transgenic 
Caenorhabditis elegans expressed wild-type, P301L, or V337M tau in the 1N4R background 
(197).  Expression of these constructs resulted in isolation of insoluble tau aggregates from the 
worms with more insoluble tau associated with the worms expressing FTDP-17 tau.  In addition 
the worms displayed motor defects, indicative of neuronal dysfunction.  Other models expressed 
0N3R or 0N4R wild-type isoforms or 0N4R-R406W tau in the mechanosensory neurons (198).  
The worms expressing the mutant tau displayed greater dysfunction surrounding the 
morphologies and sensitiveness of those neurons, an effect which was exacerbated upon 
activation of GSK-3β in an isoform-specific manner.  Aggregates were more prevalent in FTDP-
17 transgenic worms but the aggregates were not filamentous.  Additionally, neurodegeneration 
occurred in the presence and the absence of aggregates and with wild-type and mutant tau.  
Another model utilized the ΔK280 FTDP-17 mutation as a pro-aggregant form of tau and 
compared to a mutated form of tau that is unable to polymerize (199).  The ΔK280 worms 
displayed much more aggregated tau as well as neuronal dysfunction when compared to the anti-
aggregant tau, demonstrating the importance of aggregation to toxicity.  This provides an 
example of utilizing multiple forms of tau in a model organism to answer a specific question 
about the toxicity of the protein and its aggregation. 
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1.9.3 Potential issues with model organisms 
As demonstrated by the previous sections, there are many ways to generate animal models of 
tauopathies.  These models can differ based on the presence of wild-type or mutant tau, the 
FTDP-17 mutation, which isoform is expressed, and what types of cells are expressing the tau 
gene.  Evidence suggests that each of these factors may affect how, when, and where tau 
aggregates and what type of effect that aggregation will have on a particular cell or organism.  
Despite the possibility that these variables may be altering phenotypes in a manner that is not 
comparable to others, the models are often used interchangeably.  This can complicate 
interpretation of results from different studies and can cloud some of the questions surrounding 
tauopathies.  For example, the presence of NFTs was thought to be toxic to cells for many years 
until the creation of models that displayed toxicity without the large inclusion bodies cast doubt 
on this assumption. The answer to which species of tau is most toxic to neurons remains 
unresolved.  The use of an FTDP-17 form of tau that forms one type of aggregate may not have 
the same effect as the use of another mutant that forms of a different type of aggregate.  These 
differences between the two types of tau may affect the toxicity associated with a particular 
model and make answering these questions more difficult without knowing more about model-
specific effects. 
 
The choice of the isoform background is another aspect of generating models of tauopathies that 
may play a key role in the pathology associated with that particular model.  Many studies have 
demonstrated that the tau isoforms have individual differences.  For example, the 4R tau 
isoforms are more efficient at binding microtubules and aggregate more quickly than the 3R 
isoforms according to in vitro assays (200, 201).  Similarly, the isoforms also interact differently 
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when together.  Cross-seeding between 3R and 4R isoforms may not occur as efficiently as 
aggregation among like-types of tau (202), endogenous mouse tau can be incorporated into 
aggregates found in transgenic mice expressing one of the 4R human tau isoforms (179), and the 
presence of silent FTDP-17 tau mutations indicates that alteration of isoform expression levels is 
sufficient to induce tau aggregation in humans.    
 
1.10 Thesis overview 
Tauopathies are complex diseases and it is still not well known what initiates tau aggregation, 
why pathologies within this group of disorders are so varied, or what is the mechanism linking 
tau aggregation to its toxicity.  Some of the difficulties involved in generating in vivo models of 
tauopathies have hampered efforts to find conclusive answers to these questions.  First, it can be 
difficult to induce aggregation of the protein.  This problem is typically solved by overexpressing 
modified versions of tau that can include FTDP-17 mutants or truncations.  However, the 
mechanisms behind why these modified versions display increased aggregation are not well 
understood and it is possible that they do not correlate well to the behavior of wild-type tau in 
sporadic tauopathies.  Second, it can be difficult to recapitulate certain aspects of human disease 
such as NFT or neuronal death.  The pathologies of the various tauopathies are highly variable in 
humans and the current animal models can vary widely as well.  The variability may arise in part 
from intrinsic differences within the types of tau used in the models.  Elucidating differences 
between how the aggregation and function of tau are affected by these modifications can help 
explain the mechanisms of aggregation and its resulting toxicity.  This information is relevant to 
understanding differences that exist in animal models of the disease as well as the progression of 
tauopathies in humans.   
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The studies described here were designed to characterize how the aggregation and functions of 
the tau protein are affected by isoform type or FTDP-17 mutation.  They are part of a larger 
effort to use this information to examine how differences between these tau variants may be 
affecting pathology phenotypes and our interpretation of results from animal models of 
tauopathies.  In addition, characterizing these differences will assist in elucidating the 
mechanisms of the initiation of tau aggregation as well as how it may be exerting its toxic 
effects.  It is hoped that understanding these mechanisms will aid in the search for treatments of 
these diseases. 
 
The study began with in vitro characterization of tau aggregation and function.  One of the most 
obvious differences between normal tau and aggregated, disease-associated tau is the level of 
phosphorylation.  Hyperphosphorylation of tau clearly affects its function and aggregation but 
that effect may not be the same for all six isoforms and could potentially affect the differential 
aggregation that is seen in some tauopathies.  Seven pseudophosphorylation mutations were 
generated in each of the six isoforms.  This combination of seven mutations was previously 
demonstrated to affect the conformation, aggregation, and function of tau in the 2N4R tau 
isoform.  Through several assays designed to measure and characterize the aggregation of the 
protein, as well as its ability to stabilize microtubule polymerization, I determined differences in 
how the isoforms were affected. 
 
Second, I examined how various FTDP-17 mutations affected tau.  The in vitro polymerization 
of some mutated forms of tau had been characterized individually but a larger-scale direct 
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comparison had not been performed.  A determination of mutation-specific effects could 
elucidate some of the initial causes of tau aggregation and demonstrate that changes to certain 
intrinsic properties of the protein can affect aggregate morphologies and potentially how the 
disease pathology progresses throughout the brain.  These mutations are also often used 
interchangeably in animal models with little consideration about the potential intrinsic 
differences between the protein variants.  These differences in how the mutations affect 
aggregation could explain the variable pathologies associated with FTDP-17 disorders and be 
applicable to sporadic tauopathies as well.   
 
Finally, I began a project that expanded this work into a C. elegans system.  Generating 
transgenic animals expressing various forms of tau is the first step in a larger project.  The results 
from the in vitro biochemical assays will be used to determine how certain properties inherent in 
a particular variant of tau affect the disease pathology in an in vivo model.  Differences in 
aggregate type or ability to interact with microtubules could be isolated and examined in similar 
organisms. 
 
The main focus of research into tau-targeted therapeutics has focused on inhibitors of tau 
aggregation or phosphorylation under the assumption that large tau aggregates are toxic to the 
cells.  However, some aggregation inhibitors may be preventing the formation of NFT by 
trapping the tau aggregates in a more toxic oligomeric state, potentially promoting disease 
progression rather than preventing it.  Discovering the root causes of tau aggregation, how this 
aggregation is exerting its toxic effect, and what conditions lead to the differences in aggregate 
31 
 
morphology, isoform content, and location are some of the most pressing questions facing 
researchers today.   
 
The use of in vitro techniques allows us to characterize the types of tau aggregates formed and 
what effects the modifications have on the function of the protein.  The knowledge that is gained 
through these biochemical studies can then be applied to in vivo systems in order to examine the 
mechanisms of toxicity and explore potential differences between various animal models as a 
result of the type of tau expressed.  Because we have an understanding of the types of aggregates 
that are formed by a particular FTDP-17 mutant and know how its interactions with microtubules 
are affected we can then design experiments to test how those aspects fit into toxicity of tau 
aggregation in an actual neuron.  For example, one particular FTDP-17 mutation may induce 
smaller aggregates while another forms long fibers but both have no effect on microtubule 
interactions.  Comparing these two tau variants in a similar animal background can provide 
evidence about the relative toxicities of the aggregates associated with each type of mutant and 
the driving forces behind this toxicity. 
 
These studies demonstrate that similar pseudophosphorylation patterns do not induce the same 
effects on all isoforms and are sufficient to induce differential propensities for aggregation as 
well as morphological differences among the types of aggregates formed.  FTDP-17 mutant 
versions of tau were very different from each other in the ways that they aggregated and 
stabilized polymerization of microtubules.  The differences are likely to be an important factor in 
the progression of the familial frontotemporal dementias and may explain why the pathologies 
associated with the mutations are so widely varied.  Finally, the type of tau expressed in 
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nematodes seems to alter the behavior, lifespan, and neuronal defects of the animals.  This 
characterization of aggregation and function of various forms of tau is an important step toward 
elucidating the mechanisms of disease initiation and progression as well as how these differences 
may be affecting animal models of tauopathies. 
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Table 1.1 Known FTDP-17 Tau Missense Mutations 
Missense Mutation Location Exon 10 Splicing Effect Phenotype 
R5H Exon 1 No Change FTDP-17 
R5L Exon 1 No Change PSP-like 
K257T Exon 9, MTBR 1 No Change PiD-like 
I260V Exon 9, MTBR 1 No Change FTDP-17, 4R tau 
L266V Exon 9, MTBR 1 Decreased PiD-like 
G272V Exon 9, MTBR 1 No Change FTDP-17 
G273R Exon 9, MTBR 1 Unknown No tau pathology? 
N279K Exon 10, IR 1-2 Increased PSP-like 
ΔK280 Exon 10, IR 1-2 Decreased FTDP-17 
N296H Exon 10, IR 1-2 Increased FTDP-17 
ΔN296 Exon 10, MTBR 2 No Change PSP-like 
P301L Exon 10, MTBR 2 No Change FTDP-17 
P301S Exon 10, MTBR 2 No Change CBD-like, FTDP-17 
P301T Exon 10, MTBR 2 Unknown Unknown 
G303V Exon 10, MTBR 2 Increased PSP-like 
S305N Exon 10, MTBR 2 Increased CBD-like 
L315R Exon 11, IR 2-3 No Change PiD-like 
K317M Exon 11, IR 2-3 No Change PSP-like 
S320F Exon 11, IR 2-3 No Change PiD-like 
P332S Exon 11, MTBR3 No Change PiD-like/AD-like 
G335V Exon 11, MTBR3 Unknown Unknown 
G335S Exon 11, MTBR3 No Change FTDP-17? 
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Table 1.1 (Cont.)    
Missense Mutation Location Exon 10 Splicing Effect Phenotype 
Q336R Exon 12, MTBR3 No Change PiD-like 
V337M Exon 12, MTBR3 No Change FTDP-17 
E342V Exon 12, IR 3-4 Increased PiD-like, FTDP-17 
S352L Exon 12, IR 3-4 No Change Atypical 
P364S Exon 12, MTBR4 Unknown Unknown 
G366R Exon 12, MTBR4 Unknown Unknown 
K369I Exon 12 No Change PiD-like 
G389R Exon 13 Increased/No N-terminal exons PiD-like 
R406W Exon 13 No Change PSP-like 
    
    
    
    
    
    
Adapted from Alzforum.org and Cummings and Altman, 2005 (181). 
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Chapter II 
Differential effects of pseudohyperphosphorylation on tau isoform aggregation and 
function 
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Chapter II Differential effects of pseudohyperphosphorylation on tau isoform aggregation 
and function 
2.1 Abstract 
The microtubule-associated protein tau exists as six isoforms created through the splicing of the 
second, third, and tenth exons.  Hyperphosphorylated tau isoforms accumulate in insoluble 
aggregates in Alzheimer’s disease and other tauopathies. These neurodegenerative diseases can 
be categorized based on the isoform content of the aggregates they contain.  
Hyperphosphorylated tau has the general characteristics of an upward electrophoretic shift, 
decreased microtubule binding, and an association with aggregation.  Previously we have shown 
that a combination of seven pseudophosphorylation mutations at sites phosphorylated by GSK-
3β, referred to as 7-Phos, induced several of these characteristics in full-length 2N4R tau and led 
to the formation of fewer but longer filaments.  I sought to determine whether the same 
phosphorylation pattern could cause differential effects in the other tau isoforms, possibly 
through varied conformational effects.  Using in vitro techniques, I examined the electrophoretic 
mobility, aggregation properties and microtubule stabilization of all isoforms and their 
pseudophosphorylated counterparts.  I found that pseudophosphorylation affected each isoform 
but often inducing changes of varying magnitude or even completely opposite effects.  
Aggregation was inhibited for 3R isoforms but generally enhanced for 4R isoforms.  Filament 
morphology was altered by generally increasing the length of the filaments that were formed in 
aggregation assays.  Inclusion of N-terminal exons magnified inhibitory effects on the ability of 
tau to stabilize the assembly of microtubules.  These results suggest that hyperphosphorylation 
pattern of tau could play a major role in determining the isoform composition of tau aggregates 
in disease and alter the downstream pathologies. 
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2.2 Introduction 
The primary function of the tau protein is assisting in the assembly and stabilization of 
microtubules (1).  The protein likely affects the spacing and localization of microtubules as well, 
a function that could be dependent on differences in length of the six isoforms.  These isoforms 
are generated through alternative mRNA splicing of the second, third, and tenth exons (203).  
The second and third exons reside near the N-terminus of the protein and isoforms can be 
classified based on the presence or absence of these exons.  If both exons are present the protein 
is referred to as 2N, if only the second exon is present it is known as 1N, and if neither is present 
it is classified as 0N.  Exon 10 contains one of four microtubule-binding repeat regions (MTBR).  
If this exon is present in the isoform the protein is referred to as 4R and if it is absent the protein 
is classified as 3R (204).   
 
In addition to affecting the spacing of microtubules, the various tau isoforms are involved in 
certain neurodegenerative diseases.  In these disease states, tau dissociates from microtubules 
and aggregates inside of neurons, leading to neurodegeneration (13, 205).  This group of 
disorders is collectively known as tauopathies.  Tauopathies can be classified based on the 
isoform content and phosphorylation pattern found in tau aggregates (205).  While aggregates 
from Class I tauopathies contain all six isoforms, Class II aggregates are characterized by a 
larger ratio of 4R to 3R tau, and Class III tauopathies are associated with aggregates containing 
mostly 3R isoforms.  The Class III tauopathies are also characterized by a lack of 
phosphorylation at the 262 and 356 serine residues (92, 206).  Aggregates from the fourth class 
of tauopathies typically contain only 0N isoforms (205).  The various tauopathies can give rise to 
vastly different pathological effects and the changes in isoform content seen in the aggregates 
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could play a role in affecting these variations.  While the root causes of differential isoform 
inclusion into pathological aggregates are unknown, it is possible that phosphorylation of the 
isoforms could differently alter their function and activity sufficiently to contribute to this 
phenomenon.   
 
Several links between phosphorylation of tau and the pathology of Alzheimer’s disease (AD) and 
other tauopathies have been described.  A potential important factor is the increase in 
hyperphosphorylated tau found in AD-affected brains.  Hyperphosphorylated tau can be 
identified by an upward electrophoretic mobility shift, even in the presence of SDS, and a 
decreased ability to stabilize microtubule assembly (122, 207).  It is probable that several kinases 
and phosphatases are involved in generating hyperphosphorylated tau, but one kinase likely to be 
involved is glycogen synthase kinase 3β (GSK-3β) due to its association with the formation of 
neurofibrillary tangles and paired-helical filaments found in AD (208-210).  In addition, several 
sites commonly found to be phosphorylated in pathogenic tau are known to be phosphorylated by 
GSK-3β (128, 139). 
 
While the general effects of kinases are known, it can be difficult to study phosphorylation at 
specific sites in order to determine the effects they can have on the function and in vitro 
aggregation of the protein because it is nearly impossible to control the level and specific 
location of kinase activity on tau due to the large number of phosphorylation sites and the 
relative promiscuity of kinases toward tau (127, 129, 211, 212).  This can complicate collection 
and interpretation of data.  One method used to circumvent this issue is to utilize site-directed 
mutagenesis to create pseudophosphorylation mutants by changing a serine or threonine to an 
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aspartic acid or glutamic acid in order to mimic the size and the shape of a phosphate molecule 
(146, 147).  Although the effects of pseudophosphorylation may not completely replicate the 
effects of actual phosphorylation events, the technique has previously been utilized effectively to 
examine conformational changes in the protein and behavioral effects that may arise from these 
changes (54, 151, 156, 157, 160, 162, 213).   
 
A combination of pseudophosphorylation mutations, referred to as 7-Phos for the seven specific 
sites mutated, were previously created in 2N4R full-length tau (160). The 7-Phos mutation alters 
the following residues, numbered according to their position in 2N4R tau: S199E, S202E, 
T205E, T231E, S235D, S396E, and S404E.  Five of these sites are phosphorylated by GSK-3β 
when the kinase is incubated in vitro with arachidonic acid-induced pre-polymerized tau and the 
S202 and S235 sites are often phosphorylated in conjunction with the S199 and T231 sites (160, 
208).  All of the selected sites are phosphorylated at elevated levels in AD and the combination 
of these mutations replicated several aspects of pathogenic tau (212).  The 7-Phos mutations, in 
2N4R tau, were shown to induce an electrophoretic mobility shift similar to that of the 
hyperphosphorylated protein seen in AD.  Additionally, the 7-Phos mutation caused a decrease 
in the 2N4R tau isoform’s affinity for microtubules and inducer-initiated nucleation of tau 
polymerization (160). 
 
As described above, the pathology of tauopathies can vary based on the isoform content of their 
aggregates and tau phosphorylation patterns differ between the four classes of the diseases as 
well.  The six isoforms have differences in their primary structures which could place the same 
phosphorylation sites in different structural contexts.  Therefore, phosphorylation at the same 
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sites, but in different isoforms, could have widely varied effects on their conformation.  These 
conformational changes could be sufficient to cause some isoforms to dissociate from 
microtubules and aggregate while others maintain their normal function, as seen in some 
tauopathy classes. 
 
In this study I demonstrate that the 7-Phos mutation does affect the isoforms differently.  The 
SDS-resistant upward shift in electrophoretic mobility was present in all isoforms but differed in 
magnitude.  The mutation enhanced the polymerization of isoforms such as 0N4R while greatly 
inhibiting the aggregation of the 3R isoforms.  The mutation also decreased the microtubule 
stabilization function of all isoforms but affected 0N4R less than the other five.  These results 
suggest that phosphorylation patterns generated by the same set of kinases or phosphatases could 
be sufficient to increase the propensity of some isoforms to aggregate while reducing the 
aggregation of others, resulting in the differential isoform inclusion in pathological tau 
aggregates.   
 
2.3 Experimental Procedures 
2.3.1 Protein purification and site-directed mutagenesis. All wild-type and 
pseudophosphorylated mutant proteins were expressed and purified as described previously 
(150).  The pT7C-tau plasmids were transformed into BL21 E. coli and grown in 1800 mL Luria 
Broth (LB) + ampicillin until an OD600 of 0.7-0.8 is reached.  Protein translation is induced by 
adding IPTG to 1 mM.  The cells are centrifuged and resuspended in buffer (500 nM NaCl, 10 
mM Tris pH 8, 5 mM imidazole, and protease inhibitors) before being lysed with a French Press.  
Purification occurs by using an Acta fast protein liquid chromatography system.  The protein is 
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tagged with a 6x-histidine tag that binds to nickel when passed through an affinity column before 
being released in Elution Buffer (500 mM NaCl, 10 mM Tris base pH 8, and 250 mM 
imidazole).  The protein is then further purified by running it through a size-exclusion column in 
Sup200 Buffer (250 mM NaCl, 10 mM Hepes pH 7.64, and 0.1 mM EGTA, 0.1 mM DTT).  The 
protein is aliquoted and frozen at -80°C before use.  The mutations were made utilizing the 
Quikchange site-directed mutagenesis kit from Stratagene (La Jolla, CA).  The following 
mutations were made in each of the 6 isoforms in order to create the “7-Phos” mutants: S199E, 
S202E, T205E, T231E, S235D, S396E, and S404E.  Polymerization was induced using 
arachidonic acid (ARA) from Cayman Chemicals (Ann Arbor, MI). 
 
2.3.2 SDS-PAGE.  Each protein sample was incubated in buffer containing 2% SDS and 1% β-
mercaptoethanol and then boiled for five minutes.  One μg of each protein was loaded onto a 
10% SDS-PAGE and resolved through electrophoresis.  The urea-denatured protein samples 
were incubated in buffer containing 2% SDS, 1% β-mercaptoethanol, and 6 M urea (160).  The 
protein samples were resolved on a 10% SDS-PAGE with 6 M urea and stained with Coomassie 
Brilliant Blue R-250. 
 
2.3.3 ARA-induced Polymerization. Recombinant tau protein was incubated in polymerization 
buffer containing 10 mM HEPES (pH 7.64), 5 mM DTT, 100 mM NaCl, 0.1 mM EDTA, and 
3.75% ethanol. Arachidonic acid was used as an inducer of tau polymerization.  The effects of 
altering protein or ARA levels were found by varying final protein concentration from 0 to 4 μM 
with 75 μM ARA or varying the final ARA concentration from 0 to 150 μM with 2 μM protein 
(209).  Based on these results a combination of 2 μM protein and 75 μM ARA were used in 
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subsequent experiments in order to approach maximum polymerization for each tau isoform and 
its corresponding 7-Phos mutant.   
 
2.3.4 Thioflavin S fluorescence.  Polymerization was measured by utilizing staining with 
thioflavin S (ThS) from Sigma-Aldrich (St. Louis, MO).  Polymerization reactions were 
incubated for 18 hours at 25 °C.  ThS was then added to the reactions in 96-well plates to a final 
concentration of 20 μM.  The shift in fluorescence was measured with an excitation wavelength 
of 440 nm and an emission wavelength of 520 nm using a Cary Eclipse Fluorescence 
Spectrophotometer (Varian Analytical Instruments, Walnut Valley, CA).  The PMT voltage was 
set to 650 V but the procedure was otherwise performed as described earlier (150).   
 
2.3.5 Right-angle Laser Light Scattering.  Polymerization reactions were transferred to 5 mm x 
5 mm optical glass fluorometer cuvettes (Starna Cells, Atascadero, CA).  The cuvettes were 
placed in the path of a 12 mW solid state laser at λ = 532 nm and operating at 7.6 mW (B&W 
Tek, Inc., Newark, DE).  The level of polymerization was measured by capturing images of light 
scattered perpendicular to the beam using a SONY XC-ST270 digital camera.  The images were 
captured at an aperture setting of f5.6-8. The intensities of the images were quantified using 
Adobe Photoshop CS5 version 12.0.1 (214, 215). 
 
2.3.6 ARA-Induced Polymerization Kinetics.  Polymerization reactions with 2 μM protein and 
75 μM ARA, at the same reaction conditions described earlier, were mixed in 5 mm x 5 mm 
optical glass fluorometer cuvettes.  Polymerization was measured at regular time intervals 
through right-angle laser light scattering (LLS) until an apparent steady-state was reached (160).   
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2.3.7 Transmission Electron Microscopy.  The polymerization reaction samples were diluted 
1:10 in polymerization buffer with glutaraldehyde added to a final concentration of 2%.  After 
the five minute fixation with glutaraldehyde, 10 μL of each sample was added to a formvar 
carbon-coated grid for one minute.  The grid was blotted on filter paper, washed with water, 
blotted, washed with 2% uranyl acetate, and blotted dry again.  The grid was then stained with 
2% uranyl acetate for one minute and blotted dry on the filter paper again.  The grids were 
examined with a TECNAI G
2
 20 electron microscope (FEI Co., Hillsboro, OR) and images were 
taken with the Gatan Digital Micrograph imaging system.  The images were collected at a 
magnification of 3600X.  The filament numbers and areas were quantified through the use of 
Image-Pro Plus 6.0 (160). 
 
2.3.8 Tubulin Polymerization Assay.  Polymerization of tubulin was measured by utilizing the 
Tubulin Polymerization Assay kit from Cytoskeleton, Inc. (Denver, CO).  The reactions were 
measured in 96-well Costar black polystyrene flat-bottom plates (Corning, Inc., Corning, NY).  
Each well contained GTP at 1 mM and tubulin at 2 mg/mL in an 80 mM PIPES buffer (pH 6.9) 
with 2 mM MgCl2 and 0.5 mM EGTA.  Each of the wild-type or 7-Phos isoforms was added to a 
different well at a final concentration of 1 μM.  Another well contained 1 μM paclitaxel in order 
to act as a positive control for polymerization and as a standard for normalizing the results for 
each of the other reactions.  The two negative control reactions contained tubulin with no 
additional compound added.  Upon addition of the protein or control reagent to the other wells, 
the plate was placed at 37 ⁰C and shaken for 5 seconds in a FlexStation II Fluorometer 
(Molecular Devices Corporation, Sunnyvale, CA).  The fluorescence was measured every minute 
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for one hour with a λex of 355 nm and a λem of 455 nm.  The resulting data were fit to the 
Gompertz equation 
       
 
    
 
as described in (160).  The maximum amount of polymerization is found 
as a, the time from the initiation of the reaction to when polymerization is measured, or lag time, 
is calculated as ti – b, and kapp is equal to 1/b and proportional to the maximum rate of 
polymerization.  These parameters were used to describe the characteristics of the 
polymerization curve. 
 
2.4 Results 
2.4.1 Generation of 7-Phos Mutants for All Tau Isoforms   
Pseudophosphorylation mutants were generated in all six tau isoforms by making S199E, S202E, 
T205E, T231E, S235D, S396E, and S404E mutations (Figure 2.1A).  The mutants were analyzed 
by SDS-PAGE and found to exhibit an upward mobility shift as had been previously described 
for the 2N4R isoform (160).  All 7-Phos isoforms displayed a decrease in electrophoretic 
mobility when compared to their corresponding wild-type protein (Figure 2.1B).  However, upon 
addition of 6 M urea, the upward mobility shift in the 7-Phos proteins was still present but 
largely decreased for all isoforms (Figure 2.1C).  The electrophoretic shifts, in the absence of 
urea, were similar for all isoforms but slightly increased with the presence of additional N-
terminal exons (Figure 2.1D).    Because the wild-type and 7-Phos proteins have more similar 
migration distances in the presence of 6 M urea, but not in its absence, it is likely that the 7-Phos 
mutations are inducing an SDS-resistant conformational change in the proteins that can be 
interrupted with urea.  This pseudophosphorylation-induced conformational change is the cause  
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Figure 2.1 
 
Figure 2.1. 7-Phos induces an SDS-resistant electrophoretic shift in all tau isoforms. (A) Six 
isoforms of tau are created through alternative mRNA splicing of the second, third and tenth 
exons.  The latter contains the second of four microtubule-binding regions.  
Pseudophosphorylation mutations were made at seven sites commonly phosphorylated in 
Alzheimer’s disease.  This combination of mutations is referred to as 7-Phos. (B) 1 μg of the 
wild-type and 7-Phos variants for each of the six isoforms separated via 10% SDS-PAGE.  MW 
refers to the molecular weight markers.  The isoforms are labeled above the lanes with WT 
indicating wild-type protein and 7P indicating 7-Phos protein for each isoform. (C) The same 
amount of protein loaded onto a 10% SDS-PAGE with 6 M urea.  (D) The mean values of the 
electrophoretic shifts (y-axis, in kDa) for each isoform (labeled below x-axis) separated via 10% 
SDS-PAGE.  These values were calculated by subtracting the apparent molecular weight of wild-
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type isoforms from the apparent molecular weight of the corresponding 7-Phos isoforms.  Bars 
represent the mean shift from three gels with the standard deviation. 
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of the slowed electrophoretic migration and is similar to the retardation evident in 
hyperphosphorylated tau associated with disease. 
 
2.4.2 Pseudohyperphosphorylation differentially affects ARA-induced polymerization of 
isoforms 
In vitro experiments were performed to determine the effects of the 7-Phos mutation on the 
ARA-induced polymerization of the six isoforms.  The concentration of the inducer was held 
constant and the protein concentration varied from 0-4 μM.  The amount of polymerization 
generally increased with increases in protein concentration (Figures 2.2 and 2.3).  The 7-Phos 
mutants containing only three MTBRs, or 3R isoforms, polymerized less than their 
corresponding wild-type 3R isoforms when measured by ThS staining (Figure 2.2A-C) and right-
angle LLS (Figure 2.3A-C).  In contrast, the 1N4R and 2N4R 7-Phos isoforms polymerized more 
similarly to their corresponding 1N4R and 2N4R wild-type proteins (Figures 2.2E-F and 2.3E-F) 
as compared to the 3R isoforms (compare Figures 2.2A-C, E-F and 2.3A-C, E-F).  Unlike any of 
the other isoforms, the 0N4R 7-Phos protein polymerized more than its corresponding wild-type 
for most protein concentrations (Figures 2.2D and 2.3D). 
 
To determine whether the 7-Phos modification altered the response to different concentrations of 
the inducer, the protein concentration was held constant and the concentration of inducer was 
varied from 0 μM to 150 μM. Data of this nature generally has a biphasic shape, with increasing 
polymerization up to a maximum level as the inducer concentration increases.  After this 
maximum of polymerization is reached, any further addition of inducer decreases the amount of 
polymerization compared to the peak.  The biphasic nature of inducer-mediated tau  
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Figure 2.2 
 
 
Figure 2.2.  Polymerization of varied tau concentrations measured by thioflavin S staining. 
Wild-type (closed circles •) and 7-Phos tau isoforms (open squares □) polymerization reactions 
with 0 to 4 μM protein (x-axis) and 75 μM arachidonic acid were measured by thioflavin S 
fluorescence (y-axis) after 18 hours incubation at 25 °C.  Individual graphs are shown for (A) 
0N3R, (B) 1N3R, (C) 2N3R, (D) 0N4R, (E) 1N4R, and (F) 2N4R isoforms.  Bars represent the 
mean from 3 experiments ± standard deviation. 
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Figure 2.3 
 
Figure 2.3.  Polymerization of varied tau concentrations measured by right-angle laser light 
scattering. Wild-type (closed circles •) and 7-Phos tau isoform (open squares □) polymerization 
reactions with 0 to 4 μM protein (x-axis) and 75 μM arachidonic acid were measured by intensity 
of right-angle laser light scattering (y-axis) after 18 hours incubation at 25 °C.  Individual graphs 
are shown for (A) 0N3R, (B) 1N3R, (C) 2N3R, (D) 0N4R, (E) 1N4R, and (F) 2N4R isoforms.  
Data are the mean from 3 experiments and bars represent ± s.d. 
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polymerization has been previously reported (209, 216).  The polymerization for each of the 3R 
7-Phos isoforms was lower than their corresponding non-modified 3R proteins, as measured by 
ThS staining (Figure 2.4A-C).  Additionally, the 3R 7-Phos isoforms required a higher inducer 
concentration to reach maximum polymerization than the 3R wild-type isoforms.  When the 
polymerization was measured by LLS, very little polymerization was detected for any of the 3R 
7-Phos isoforms while the wild-type 3R isoforms also displayed the biphasic curve but with a 
sharp increase at the highest inducer concentrations (Figure 2.5A-C).  Because these increases in 
light scattering, primarily seen at the 150 μM ARA concentration, are not replicated when 
measured by ThS staining (Figure 2.4A-F) or transmission electron microscopy (data not shown) 
they are likely due to formation of ARA micelles and not increased tau polymerization.  
Additionally, in Figures 2.4 and 2.5, the ARA to protein ratio has greatly been altered which has 
been shown to affect ThS and LLS readings differently (209). 
 
The polymerization of 0N4R 7-Phos was greater than its corresponding wild-type at the higher 
inducer concentrations tested when measured by ThS fluorescence (Figure 2.4D).  However, the 
LLS measurements indicated that polymerization of the 0N4R 7-Phos isoform was greater than 
that of the 0N4R wild-type isoform at 50 and 100 μM ARA but less than wild-type at the higher 
concentrations tested.  The polymerization curves for 1N4R and 2N4R wild-type and 7-Phos 
variants were more similar to one another than what was observed for the other isoforms (Figure 
2.4E-F and Figure 2.5E-F).   
 
Any discrepancies between ThS staining and LLS readings could be due to subtle differences in 
how measurements from the two methods are affected by changes in length or other  
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Figure 2.4 
 
Figure 2.4.  Polymerization of 2 μM tau with 0 to 150 μM ARA measured by thioflavin S 
fluorescence. Wild-type (closed circles •) and 7-Phos tau isoform (open squares □) 
polymerization reactions with 2 μM protein and 0 to 150 μM arachidonic acid (x-axis) were 
measured by thioflavin S fluorescence (y-axis) after 18 hours incubation at 25   C.  The 
fluorescence value of the 0 μM ARA reaction was subtracted from the other values.  Individual 
graphs are shown for (A) 0N3R, (B) 1N3R, (C) 2N3R, (D) 0N4R, (E) 1N4R, and (F) 2N4R 
isoforms.  Bars represent ± s.d. from 3 experiments. 
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Figure 2.5 
 
Figure 2.5.  Polymerization of 2 μM tau induced with varied ARA concentration (0 μM to 
150 μM) measured by right-angle laser light scattering. Wild-type (closed circles •) and 7-
Phos tau isoform (open squares □) polymerization reactions with 2 μM protein (x-axis) and 0 to 
75 μM arachidonic acid were measured by intensity of right-angle laser light scattering (y-axis) 
after 18 hours incubation at 25   C.  Individual graphs are shown for (A) 0N3R, (B) 1N3R, (C) 
2N3R, (D) 0N4R, (E) 1N4R, and (F) 2N4R isoforms.  Bars represent ± s.d. from 3 experiments. 
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morphological characteristics in the population of filaments (209, 217-219).  Fewer, but longer, 
filaments may decrease the amount of light scattered but could have little change in ThS binding 
if the total amount of polymerization is similar.  In addition, changes in morphology, such as a 
change in the β-sheet structure or the formation of straight filaments rather than paired helical 
filaments, could also affect the affinity of ThS binding.  Factors other than morphology changes, 
such as the formation of ARA micelles, could also have an effect on LLS values.  Because of 
these challenges I believe that utilizing both methods, as well as transmission electron 
microscopy, will give a clearer picture of alterations in the polymerization ability of these tau 
variants. 
 
Visual inspection of the above curves revealed that most proteins at 2 μM concentration had a 
peak in polymerization either at or close to 75 μM ARA.  As these polymerization conditions are 
routinely used for in vitro tau polymerization reactions, they were chosen for further analysis of 
the effects of the 7-Phos modification on the tau isoforms (160, 173, 220).  The amounts of 
polymerization were determined after 18 hour incubation under these reaction conditions.  The 
amounts of 7-Phos protein polymerization were normalized to their corresponding wild-type 
values to obtain a percent change from wild-type (Figure 2.6A and 2.6B).  The 7-Phos 
pseudohyperphosphorylation mutation affected the 3R isoforms differently than it affected the 
4R isoforms.  The three 3R isoforms all showed a decrease in polymerization measured by ThS 
staining (Figure 2.6A) and a greater than 50% decrease in polymerization measured by LLS 
intensity (Figure 2.6B).  In contrast, the 4R isoforms all had increased polymerization levels with 
the 7-Phos mutation according to ThS fluorescence (Figure 2.6A) and an increase or very little 
change in LLS values (Figure 2.6B).   
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Figure 2.6 
 
 
Figure 2.6.  Percent change in polymerization of 2 μM 7-Phos protein and 75 μM ARA 
polymerization reactions as compared to wild-type protein.  Polymerization reactions were 
prepared with 2 μM tau and 75 μM ARA and incubated for 18 hours at 25 °C.  Polymerization 
was measured by (A) ThS fluorescence and (B) right-angle laser light scattering as described 
earlier.  Results for each isoform are labeled on X-axis.  Bars represent the average from 3 
experiments ± s.d. 
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2.4.3 Pseudohyperphosphorylation affects the number and the morphology of tau filaments 
differently among the six isoforms 
Samples of polymerization reactions under near optimal conditions (Figure 2.6) were examined 
by transmission electron microscopy to determine whether the 7-Phos mutation affected filament 
morphology (Figure 2.7).  The mutation had varying effects on both the morphology and number 
of filaments present, although no changes were apparent in filament width or structure at higher 
magnification (data not shown).  In general, filaments for the 7-Phos proteins were fewer in 
number, larger in size, and formed similar or less total mass of filaments (Figure 2.8).  The 
exceptions were 0N4R 7-Phos (more filaments, more total mass) (Figure 2.8A and 2.8C), and 
2N3R (shorter filaments) (Figure 2.8B).  It should be mentioned that part of the effect seen on 
the number and morphology of 0N4R tau filaments is likely due to uneven distribution of wild 
type filaments, which is lessened by GSK-3β phosphorylation and is therefore likely to be 
decreased for 7-Phos 0N4R (33).   
 
2.4.4 7-Phos affects the kinetics of polymerization 
Polymerization reactions were monitored by LLS over time to measure the kinetics of 
polymerization.  Wild-type 3R isoforms had very long lag times before polymerization was 
detected (Figure 2.9A-C), while the 4R isoforms had shorter lag times and reached  maximum 
polymerization within approximately 80 minutes (Figure 2.9D-F). 
 
The maximum amount of polymerization was greatly decreased for the 3R 7-Phos isoforms 
compared to their wild-type counterparts (Figure 2.9A-C).  As expected, very little 
polymerization was detected for the 3R 7-Phos isoforms by LLS and the data could not be fit to a  
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Figure 2.7 
 
Figure 2.7. Electron Micrographs of 2 μM protein and 75 μM ARA polymerization 
reactions.  Representative electron micrographs of polymerization reactions of wild-type 
isoforms (left): (A) 0N3R, (C) 1N3R, (E) 2N3R, (G) 0N4R, (I) 1N4R, and (K) 2N4R; and 
corresponding 7-Phos isoforms (right): (B) 0N3R, (D) 1N3R, (F) 2N3R, (H) 0N4R, (J) 1N4R, 
and (L) 2N4R.  The images were taken at a magnification of 3600x and the scale bar in (L) 
represent 1 μm and applies to all images. 
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Figure 2.8 
 
Figure 2.8. Quantitation of filaments from transmission electron micrographs.  Quantitation 
of transmission electron micrographs from Figure 7 were performed as described in Materials 
and Methods.  Values for (A) total number of filaments, (B) average filament length (μm), and 
(C) total length (number x average length) are shown for wild-type (black bars) and 7-Phos 
(white bars) for each isoform (labeled on x-axis).  Data represent average values from 3 separate 
experiments ± s.d.   
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Figure 2.9
 
Figure 2.9. Kinetics of tau polymerization.  Polymerization reactions were monitored by right-
angle laser light scattering (arbitrary units, y-axis) at specific time points (minutes, x-axis) until 
the amount of polymerization approached an apparent steady-state.  The experiment was 
repeated three times for the wild-type (closed circles •) and 7-Phos (open squares □) of (A) 
0N3R, (B) 1N3R, (C) 2N3R, (D) 0N4R, (E) 1N4R, and (F) 2N4R.  The equations were fit to the 
Gompertz equation and (G) the maximum amount of polymerization, (H) the lag time, and (I) the 
polymerization rate (kapp) for each was calculated.  Isoforms are labeled on the x-axis.  Data is 
shown as normalized values to the amount of wild-type polymerization (percent change from 
wild-type) for three separate trials.  Error bars represent the s.d. from 3 experiments.  Data is not 
included for the 3R isoforms in (H) and (I) because the data could not be satisfactorily fit to the 
kinetics equation. 
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kinetics equation (see Figure 2.5A-C).  In contrast, the maximum amount of polymerization for 
the 4R 7-Phos isoforms were similar to or increased over their wild-type versions (Figure 2.9G) 
although their lag times before significant polymerization were longer (Figure 2.9H).  The rate of 
polymerization was also slower (Figure 2.9I).  
 
2.4.5 The ability of the protein to stabilize tubulin polymerization is affected by 
pseudohyperphosphorylation mutations 
One of the normal functions of tau is the stabilization of microtubule assembly (1, 31, 221, 222).  
Phosphorylation of the protein can decrease its affinity for microtubules as well as its ability to 
induce the polymerization of tubulin dimers into microtubules (142, 223-225).  An in vitro 
microtubule polymerization assay was used to measure the effect of the 7-Phos 
pseudohyperphosphorylation mutation on the ability of each isoform to stabilize tubulin 
polymerization (Figure 2.10A-F).   
 
The 7-Phos mutation inhibited the ability of all six tau isoforms to stabilize the polymerization of 
tubulin.  The rates of tubulin polymerization were decreased (Figure 2.10G), the lag times 
required to initiate microtubule polymerization were increased (Figure 2.10H), and the amounts 
of overall tubulin polymerization were reduced (Figure 2.10I).  Of these, 7-Phos 0N4R seemed 
to be the least affected in all aspects. 
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Figure 2.10 
 
Figure 2.10. Tau isoform stabilization of microtubule polymerization.  The ability of wild-
type (•) and 7-Phos (□) tau isoforms to stabilize the polymerization of tubulin into microtubules 
was measured using a fluorescence assay.  The relative fluorescence units (y-axis) are plotted 
against time (x-axis) for (A) 0N3R, (B) 1N3R, (C) 2N3R, (D) 0N4R, (E) 1N4R, and (F) 2N4R.  
Data points represent 3 separate trials ± s.d.  The data was normalized to paclitaxel controls 
(crosshatches) that were performed in addition to tau reactions.  Tau/tubulin reactions did not 
contain paclitaxel.   Kinetics parameters were calculated from each of the three trials and the 
means of the percent change from wild-type with the addition of 7-Phos for (G) the kapp, or 
polymerization rate, (H) lag time, or the time from initiation of the reaction until polymerization 
is detected, and (I) the maximum polymerization after 60 minutes are shown ± s.d.  
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2.5 Discussion 
The major common feature among neurodegenerative tauopathies is the polymerization of the 
tau protein into filamentous aggregates.  While these aggregates are present in all tauopathies, 
the diseases can differ in the combination of tau isoforms included.  The various combinations of 
isoforms present within the tangles can be used to classify the neurodegenerative tauopathies 
(205), indicating aggregation selectivity of certain isoforms in particular tauopathies.  The causes 
of selective aggregation of tau isoforms are unknown but it is possible that phosphorylation plays 
an important role. 
 
Phosphorylation of tau has long been associated with aggregation of tau in neurodegenerative 
tauopathies.  The pathological tau found in neurofibrillary tangles is often hyperphosphorylated 
(67, 123).  Kinases, such as GSK-3β, may display increased activity in Alzheimer’s disease (226) 
and are associated with neurofibrillary tangles (132).  In addition, the activities of phosphatases, 
such as PP2A, are decreased in many tauopathies (227, 228).  The phosphorylation of tau can 
have profound effects on its conformation.  Although tau typically exists as a natively unfolded 
protein, it has been shown to adopt a global hairpin conformation with the N- and C-termini 
folding over to interact with its MTBR (54).  Pseudophosphorylation at certain sites can affect 
the compaction of the protein (157, 229).  Because the isoforms of tau differ from each other by 
up to 89 amino acids (20-25%), it is reasonable that similar levels or similar patterns of 
phosphorylation could have significantly different effects on the isoform conformations and 
functions.   
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Pseudophosphorylation can provide a useful way to explore the effects of site-specific 
phosphorylation on the conformation and function of a protein.  However, I also recognize that it 
may not exactly replicate an actual phosphorylation event and all of its effects.  While limitations 
exist and caution should be used in interpreting implications of the results, 
pseudophosphorylation can be a valuable tool to explore site-specific effects of phosphorylation 
and, indeed, has been used in multiple in vitro and cell culture studies of tau (147, 154, 229, 
230).   
 
In one such study, it has previously been reported that pseudophosphorylation mutations at seven 
sites on full-length 2N4R tau replicated certain characteristics associated with 
hyperphosphorylated tau (160).  One of these characteristics was an SDS-resistant 
electrophoretic mobility shift, likely due to a conformational change in the protein altering the 
accessibility of the protein backbone to SDS.  The pseudophosphorylation mutations at the seven 
sites also negatively affected the normal interaction of the protein with microtubules compared to 
wild-type 2N4R tau (160).  In addition, the 7-Phos mutation affected the in vitro polymerization 
of the isoform by inducing longer, but less frequent, filament formation (160). I therefore sought 
to determine whether the same level and pattern of pseudophosphorylation mutations would have 
different effects on the function of the other tau isoforms. 
 
In this study I have shown that pseudophosphorylation at seven identical sites on the backbone of 
the six tau isoforms resulted in an SDS-resistant electrophoretic shift in each protein, indicating 
that the conformation of the proteins had been altered by the 7-Phos mutation.  However, the 
magnitude of these changes was not equal.  Previous studies have shown that 
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pseudophosphorylation of 2N4R tau at the S199, S202, S205, T212, S214, S396, and S404 sites 
induce conformational changes that increase the reaction of the protein with the conformational-
dependent antibody MC1, an antibody that recognizes pathological tau associated with 
electrophoretic shifts (229, 231).  However, there are conflicting results as to whether this 
pseudophosphorylation is causing a tightening or a loosening of the hairpin conformation (157, 
229).  Our results could coincide with either model but it seems likely that a global compaction 
of tau conformation would result in regions of tau becoming inaccessible, thereby reducing SDS 
binding and slowing electrophoretic migration.  Our results would suggest that the level of 
compaction caused by pseudophosphorylation is not the same for the six isoforms, indicating that 
similar levels and sites of phosphorylation have different effects on the conformation of tau 
isoforms.  These differential effects on conformation could lead to changes in the other 
properties of the protein. 
 
In support of this, pseudohyperphosphorylation affected the ARA induction of tau 
polymerization differently among the isoforms.  The 7-Phos 3R isoforms did not polymerize as 
well as their wild-type counterparts while 7-Phos 4R isoforms polymerized as well or better than 
wild-type 4R.  This, combined with the differences in electrophoretic mobility, suggests the 
possibility that the MTBR of the 3R isoforms may be less accessible to ARA when they are in a 
conformation induced by the 7-Phos mutation.  Previous results showing that the MTBR of tau 
isoforms differ from one another both structurally and mechanistically support this supposition 
(232).  It is possible that different results could be obtained using different inducer molecules 
such as heparin, planar aromatic dyes, polyanionic microspheres, mRNA or alkyl sulfate 
detergents and these experiments should be performed in the future. 
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Because hyperphosphorylated tau is associated with aggregation in AD and other tauopathies one 
might expect that pseudophosphorylation would lead to increased polymerization in the in vitro 
reactions.  However, for most of the isoforms, polymerization was similar or decreased 
compared to the corresponding wild-type isoforms.  This could be due to the limitations of 
pseudophosphorylation as a model or the homogenous reactions give different results than a 
mixture of phosphorylated forms of tau.  However, it is also possible that similar 
phosphorylation patterns could lead to different conformational effects on the isoforms.  The 
varied conformational effects could then lead to increased aggregation for some isoforms while 
decreasing the likelihood of aggregation for others.  Variable conformational changes could help 
explain why the isoform content of aggregates can vary by tauopathy. 
 
Compaction of the carboxy-terminus toward the MTBR would be expected to inhibit tau 
aggregation (152, 233), while compaction of the amino-terminus toward the MTBR would be 
expected to enhance tau aggregation (220, 229).  If this is the case, inhibition caused by 
compaction of the carboxy-terminus would likely be relatively similar among the isoforms since 
that region does not differ between them.  However, the compaction of the amino terminus 
caused by phosphorylation would be expected to be different between the isoforms due to the 
presence or absence of exons 2 and 3, and one would therefore expect this compaction of the 
amino terminus to have more varied effects on polymerization of the isoforms.  Indeed, 
polymerization of the 0N 7-Phos isoforms seems to be less inhibited compared to its wild-type 
counterparts than was observed for the 1N and 2N isoforms.  In fact, polymerization of the 0N4R 
7-Phos in enhanced compared to wild-type 0N4R tau under certain conditions.  The absence of 
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exons 2 and 3 could lead to a tighter compaction of the amino-terminus when these sites in the 
proline-rich region are phosphorylated.  This tighter compaction could then lead to increased tau 
aggregation.   
 
In general, the four-repeat isoforms seem to be less affected by pseudo-phosphorylation and 
compaction than the three-repeat isoforms, presumably due to the additional MTBR.  This 
additional repeat reduces the impact of conformational-dependent enhancement or inhibition of 
tau aggregation leading to similar aggregation for wild-type and 7-Phos of each isoforms.  It is 
likely that the additional repeat either results in a structural conformation that protects the MTBR 
from the amino and carboxy terminals, or that the additional repeat provides a second site for 
inducer interactions, thereby overcoming inhibition or enhancement by mass action. 
 
Other differences in the polymerization of 7-Phos isoforms existed at the optimal ratio of 2 μM 
protein and 75 μM ARA.  All of the 7-Phos isoforms polymerized more slowly than wild-type 
and fewer, but longer, filaments were formed for many of the 7-Phos isoforms.  This also 
suggests that compaction due to phosphorylation could negatively affect the ARA-induced 
nucleation of filaments but could also stabilize filament elongation.  This compaction could be 
differentially affecting the accessibility of the MTBR as discussed above, resulting in less 
nucleation and slower growth, causing the differences in morphology observed between 
isoforms.  The effect was greatest in 0N4R tau which displayed an increase in polymerization, 
number of filaments formed, and length of filaments with the 7-Phos pseudophosphorylation 
mutation.  Part of this effect could be due to increased or improved filament distribution on the 
electron microscopy grids (215) but the agreement between the SDS-PAGE migration, 
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quantitative electron microscopy, LLS, and ThS fluorescence data suggest that the 0N4R 7-Phos 
has a more accessible MTBR. 
 
Differences in accessibility of the MTBR would be expected to affect the ability of tau to 
stabilize microtubule polymerization as well.  The 7-Phos mutation caused a reduction in the 
ability of all six isoforms to stabilize microtubules.  The overall amount of tubulin 
polymerization was decreased, the lag times were increased, and the rate of polymerization was 
decreased.  The degrees of changes were not equal among the isoforms.  For example, 0N4R tau 
had much less severe defects in its ability to stabilize microtubules.  Additionally, the 0N3R 7-
Phos stabilized microtubule growth more readily than the other 3R 7-Phos isoforms did.  This 
indicates that phosphorylation of 0N isoforms could cause the MTBR to be more accessible than 
in 1N or 2N isoforms.  In general, pseudohyperphosphorylated 4R isoforms had more similar 
aggregation and microtubule stabilization characteristics as compared to their wild-type 
counterparts than the 3R isoforms.  This indicates that compaction of tau due to phosphorylation 
may be obscuring the MTBRs more for 3R isoforms than 4R isoforms.  
 
In summary, our results are consistent with similar levels and patterns of phosphorylation having 
substantially different effects on tau isoforms.  This result is important considering efforts to 
target phosphorylation as a therapeutic intervention for tauopathies.  Our results suggest that 
such therapies will have different effects on the six isoforms of tau which could lead to 
complications.  They also suggest that animal models used to study the effects of 
phosphorylation on the toxicity of tau would be affected by the choice of isoforms.  Future 
studies will be required to determine whether these results are specific to these sites and this 
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inducer or whether similar results will be obtained using alternative inducers or different sites to 
generate alternative pseudohyperphosphorylated versions of tau isoforms.     
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Chapter III FTDP-17 Tau Mutations Induce Distinct Effects on Aggregation and 
Microtubule Interactions 
3.1 Abstract 
FTDP-17 mutations in the tau gene lead to early-onset frontotemporal dementias characterized 
by the pathological aggregation of the microtubule-associated protein tau.  These mutations are 
primarily located in or near the microtubule-binding repeat regions of tau and can induce vastly 
different effects on the aggregation and function of the protein.  The pathologies associated with 
FTDP-17 can vary widely as well.  Despite this variety, several of the mutations are commonly 
used interchangeably as aggregation inducers for in vitro and in vivo models of tauopathies.  The 
recombinant forms of 12 FTDP-17 mutations, chosen for their predicted effects on the charge, 
hydrophobicity, and secondary structure of the protein, were generated.  I then examined the 
effects that the mutations induced on the properties of in vitro aggregation of the protein and its 
ability to stabilize microtubule assembly.  The group of mutations induced very different effects 
on the total amount of aggregation, the kinetics of aggregation, and filament morphology.  Total 
aggregation could be enhanced or inhibited by the mutations.  Some mutants formed primarily 
oligomeric aggregates while others formed much longer filaments.  Several of the mutations 
inhibited the microtubule-stabilizing ability of tau while others had very little effect compared to 
wild-type tau.  These results indicate that the mechanisms of disease progression may differ 
among FTDP-17 mutations.  Additionally, the effects of the varying mutations may not be equal 
in all model systems and the type of mutation and its effects should be considered when 
generating and comparing these in vivo models. 
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3.2 Introduction 
The pathological aggregation of the microtubule-associated protein tau is characteristic of the 
group of neurodegenerative disorders known as tauopathies.  Although tau can be found in a 
variety of tissues, it is predominantly found in neurons where its primary functions are to 
promote the assembly and stability of microtubules in addition to interacting with cellular 
membranes and playing a role in regulation of microtubule spacing as well as axonal transport 
(1, 37, 42, 46, 234).  The tau gene contains sixteen exons that, in the central nervous system, give 
rise to six distinct isoforms that differ by their pattern of inclusion or exclusion of exons 2, 3 and 
10.  Exon 10 encodes one of four potential microtubule-binding repeat regions (MTBR) that are 
the primary source of tau interactions with microtubules.  Each MTBR contains a highly-
conserved 18 amino acid repeat and an inter-repeat regions of 13 or 14 amino acids, both of 
which make significant contributions microtubule binding (21, 93, 204). 
 
Tau MTBR were found to comprise the core of pathologically aggregated tau filaments (235) 
and have been found to be necessary and sufficient for tau aggregation into straight and paired-
helical filaments (110, 236).  Within the MTBR, the sequences 
275
VQIINK in exon 10 and 
306
VQIVYK in exon 11 misfold into β-strands that subsequently interact with adjacent tau 
molecules to form characteristic amyloid structure (110-112, 237, 238).   The nucleation step, 
formation of oligomers, is likely the first step in tau aggregation and can be followed by a slower 
elongation phase that leads to the formation of longer straight or paired helical filaments from 
these oligomers (239, 240).  Aggregated tau then accumulates in pathological structures such as 
neurofibrillary tangles, neuropil threads, Pick bodies and others that correlate with the type and 
severity of clinical impairment in neurodegenerative tauopathies (reviewed in (8, 205)).     
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In AD and other related tauopathies, tau aggregation is oftentimes associated with other 
pathological structures such as beta-amyloid extracellular senile plaques.  It was therefore 
unclear whether tau aggregation played a role as a causative agent in neuronal cell death or was 
simply a byproduct of other toxic mechanisms.  The potential for a causative role was greatly 
strengthened with the identification of a group of mutations in the tau gene that led to early-onset 
frontotemporal dementias (80, 82).  Many of the mutations cause increased propensities for 
aggregation and decreased microtubule interactions which could represent toxic gain and loss of 
functions respectively (112, 182, 214, 241-248),  Several of the mutations have also been utilized 
in a diverse set of model organisms, including nematodes, flies, Xenopus, and mice ((192, 197, 
214, 249, 250), reviewed in (251)).  These naturally-occurring mutations have provided an 
invaluable tool to the study of tau aggregation, but their effects have not always been consistent 
across the spectrum of mutants or model organisms (252). 
 
It is possible that some of the observed differences in the effects of tau aggregation in cellular 
and animal models are a direct result of the various FTDP-17 mutations employed to generate 
aggregated tau.  Certain FTDP-17 mutations have been shown to increase the rate or total 
amount of tau aggregation both in vitro and in vivo which may be leading to early-onset 
tauopathies (192, 220, 241, 244, 253); some FTDP-17 mutants show decreased binding to 
microtubules and an impaired ability to stabilize polymerization of tubulin while others have 
little effect (242, 254).   In addition, the progression and pathologies of FTDP-17 can vary 
greatly depending on the specific mutation, indicating that initial causes of the disease may vary 
as well (reviewed in (255)).  I therefore sought to compare several FTDP-17 mutations under the 
72 
 
same conditions to determine how they affected aggregation and microtubule interaction, two 
factors that may have causative roles in the toxicity of these diseases, and whether differences in 
the intrinsic effects of FTDP-17 mutations could be correlated to these changes.  From the 25 
known FTDP-17 missense mutants of tau, we chose to model the 12 mutations predicted to have 
the most significant impact on tau charge, hydrophobicity (256) and structure (257).  Our 
predictions were based on an analysis demonstrating that these parameters were the primary 
determinants of aggregation rates (258).  These mutants were modeled in the background of full-
length 2N4R tau in vitro to provide direct side-by-side comparisons to assess the impact of the 
structural modifications.  
 
I found that the FTDP-17 mutants had very different effects on the aggregation and microtubule 
interactions of tau.  These changes in aggregate amounts, rates and morphologies could help in 
our understanding of the varied pathologies and toxicities resulting from the mutations.  While 
some of the mutations had similar effects on tau function and aggregation, I found that there was 
not a simple correlation between the effects on tau and the protein’s charge, hydrophobicity or 
predicted structure.  This indicates that predictive methods are insufficient for determining the 
impact of tau mutations on the severity of impairment. 
 
3.3 Experimental Procedures 
3.3.1 Selection of FTDP-17 mutations.  Mutations were selected based on their predicted 
changes to average hydrophobicity, charge, α-helical structure, β-strand structure, and turns. 
These predictions were calculated across 7 amino acid-long sequences for the entire 2N4R tau 
isoform using Kyte-Doolitte values to estimate hydrophobicity (256) and Chou-Fassmann 
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parameters for effects on secondary structure (257).  The effect of each mutant was ranked 
according to each of these factors and the total effect was estimated based on summation of 
rankings for each variant.  The 11 mutants predicted to have the largest effects on the structure of 
the protein were chosen along with V337M, a mutant commonly used to generate tau 
aggregation in in vivo models.  
 
3.3.2 Protein expression and purification.  All wild-type (WT) and FTDP-17 mutant protein 
was expressed and purified as described previously (150).  The FTDP-17 mutations were created 
using the Quikchange site-directed mutagenesis kit from Stratagene (La Jolla, CA). The 
following mutations were generated in a full-length 2N4R tau background contained in a pT7C 
vector: R5L, G272V, ΔN296, P301L, G303V, L315R, S320F, V337M, E342V, S352L, K369I, 
and G389R. 
 
3.3.3 Arachidonic acid-induced polymerization.  Recombinant WT and mutant tau protein, at 
a concentration of 2 μM, was incubated in buffer containing 0.1 mM EDTA, 5 mM dithiothreitol, 
10 mM Hepes buffer (pH 7.64), 100 mM NaCl, and 3.75% ethanol in a 1.5 mL microcentrifuge 
tube.  The polymerization inducer molecule was arachidonic acid (ARA) at a concentration of 75 
μM.  Reactions were allowed to proceed overnight at 25 °C. 
 
3.3.4 Thioflavin S fluorescence.  The total amount of aggregation was measured utilizing the 
binding of thioflavin S (ThS) from Sigma-Aldrich (St. Louis, MO).  150 μL of each reaction was 
added to separate wells in a 96-well, white, flat-bottom plate.  ThS was diluted in water and 
added to the well to a final concentration of 20 μM.  The fluorescence shift was measured by 
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using a Cary Eclipse Fluorescence Spectrophotometer (Varian Analytical Instruments, Walnut 
Valley, CA) with an excitation wavelength of 440 nm and an emission wavelength of 520 nm.  
PMT voltage was set to 650 V.  Readings from a reaction with 2 μM protein and 0 μM ARA 
were used as a blank and subtracted from the reading for each reaction (150). 
 
3.3.5 Right-angle laser light scattering.  Aggregation of the protein was also read by adding 
180 μL of the reaction to a 5 mm x 5 mm optical glass fluorometer cuvette (Starna Cells, 
Atascadero, CA).  A 12 mW solid state laser, with a wavelength of λ=532 nm and operating at 
7.6 mW, was aimed at the cuvette.  The amount of light scattered by particles in the reaction was 
measured by capturing the amount of light perpendicular to the angle of the beam using a SONY 
XC-ST270 digital camera.  The images were captured at varying aperture settings (from f4 to 
f11) and analyzed using the histogram function of Adobe Photoshop CS5 version 12.0.1. (214). 
 
3.3.6 ARA-induced polymerization kinetics.  ARA was added to our polymerization buffer 
(0.1 mM EDTA, 5mM dithiothreitol, 10 mM Hepes buffer (pH 7.64), 100 mM NaCl) to a final 
concentration of 75 μM and 3.75% ethanol in a 5 mm x 5 mm optical glass fluorometer cuvette.  
Tau polymerization was measured by collecting images of the right-angle scattered light at 
specific time points beginning from the initiation of the reaction upon addition of protein, at a 
final concentration of 2 μM, and the ending once the reaction had reached a steady-state.  The 
data were fit to the Finke-Watzky 2-step mechanism, designed to describe the nucleation and 
elongation of protein aggregation (259).  The mechanism assumes simplified nucleation ( 
  
→ ) and elongation (    
  
→   ) steps to yield the following equation: 
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The k1 and k2 rate constants are used to qualitatively compare the rates of nucleation and 
elongation, respectively, of our protein aggregation reactions. 
 
3.3.7 Transmission electron microscopy.  The ARA-induced polymerization reactions were 
diluted 1:10 in polymerization buffer and 2% glutaraldehyde.  After a five minute incubation, a 
formvar-coated copper grid (Electron Microscopy Sciences, Hatfield, PA) was placed on top of a 
10 μL drop of the diluted sample for 1 minute.  The grid was then blotted on filter paper, placed 
on a drop of water, blotted with filter paper, placed on a drop of 2% uranyl acetate, and blotted 
dry.  The grid was then placed on another drop of 2% uranyl acetate for 1 minute and blotted dry 
for a final time.  For all tau variants a single grid was prepared and examined from each of three 
separate reactions.  The grids were examined using a TECNAI G
2
 20 electron microscope (FEI 
Co., Hillsboro, OR).  Images were collected with the Gatan Digital Micrograph imaging system 
at a magnification of 3600X.  Five images were collected from each grid and analyzed.  The 
aggregated tau in each of the 15 images was quantified by using Image-Pro Plus 6.0.  The macro 
was designed to recognize filaments with a total perimeter of greater than 30 nm.  This captured 
what I felt were legitimate aggregates while eliminating background noise.  The perimeter of 
each filament was measured and divided by two in order to estimate the filament’s length.  These 
values were totaled in order to estimate the total amount of aggregated material in each image.   
The total polymerization/image was calculated by taking the mean of all total polymerization 
values.  The mean of all filament lengths was also determined by calculating the mean length of 
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all filaments in a given image and reported as a mean of those values with the error bars 
representing standard deviation.   
 
3.3.8 Tubulin polymerization assay.  The Tubulin Polymerization Assay kit from Cytoskeleton, 
Inc. (Denver, CO) was used to measure the polymerization of tubulin.  The reaction conditions 
included WT tau or one of the tau variants at 1 μM, or a control compound, added along with 1 
mM GTP, 2 mg/ml (~36 μM dimerized) tubulin, 2 mM MgCl2, and 0.5 mM EGTA in 80 mM 
PIPES buffer at a pH of 6.9.  The reaction proceeded in a black, flat-bottomed polystyrene 96-
well plate.  Paclitaxel was used at 3 μM in one reaction to serve as a positive control for tubulin 
polymerization, as well as a way to normalize separate reactions. One well contained no 
additional compound as a negative control.  After addition of the compounds the plate was 
inserted into a FlexStation II Fluorometer (Molecular Devices Corporation, Sunnyvale, CA) set 
at a temperature of 37 °C and the reactions were mixed by shaking for 5 seconds.  The 
fluorescence was measured with an excitation wavelength of 355 nm and an emission 
wavelength at 455 nm at 1 minute intervals for 1 hour.  The data were fit to the Gompertz 
equation 
       
 
    
 
  
as described earlier (160, 260).  The maximum amount of tubulin polymerization is described by 
a, the lag time from reaction initiation to the start of polymerization is ti – b, and kapp, or 1/b, is 
proportional to the rate of polymerization. 
 
3.3.9 Statistical analysis.  An unpaired two-tailed Student’s t-test was used to compare means of 
WT values to mean values of each mutant for thioflavin S fluorescence, right-angle laser light 
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scattering, quantitative electron microscopy, and kinetics parameters.  A paired two-tailed t-test 
was used to compare the values for the microtubule assembly assay.  P-values less than or equal 
to 0.05 were indicated with one asterisk (*), less than or equal to 0.01 with two asterisks (**), 
and less than or equal to 0.001 with three asterisks (***).  Because variation among the mutants 
is also important to consider, statistical variation in the entire groups was measured by using a 
one-way ANOVA analysis with a Tukey’s Multiple Comparison test and compiled in tables.  
The p-values for this comparison were also indicated using the asterisk system described above. 
 
3.4 Results 
3.4.1 Selection of FTDP-17 mutations 
A list of 25 known FTDP-17 mutations was generated and ranked based on the total predicted 
changes to the structure of the protein.  The 11 mutations predicted to induce the largest 
structural changes were selected along with V337M which was selected because it has 
previously been used in several model organisms.  The majority of the chosen FTDP-17 
mutations can be found within, or very near to, one of the 4 MTBR while R5L and G389R are 
found in the N- and C-terminal regions respectively (Figure 3.1). 
 
3.4.2 FTDP-17 mutations induce varying effects on total polymerization 
In vitro experiments were used to examine the effects of the 12 mutations on the ARA-induced 
polymerization of tau at 2 µM protein and 75 µM ARA (209).  After the reactions proceeded 
overnight, the total amount of aggregation was measured by ThS fluorescence and right-angle 
laser light scattering (LLS).  Half of the mutant proteins displayed an increase in ThS  
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Figure 3.1 
 
Figure 3.1. Schematic of FTDP-17 mutations in 2N4R tau.  Each of the naturally-occurring 
FTDP-17 mutations indicated in the figure was created in a full-length 2N4R tau background.  
E2, E3, and E10 represent exons that can be excluded from other tau isoforms.  Regions 
predicted to exhibit transient secondary structure are indicated by cylinders (α-helices) or arrows 
(β-strands).  Boxes R1-R4 represent microtubule-binding repeat regions. 
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fluorescence compared to WT tau protein (G272V, P301L, G303V, S320F, S352L and G389R), 
indicating that more protein had polymerized in those reactions.  Others had levels of  
polymerization that were similar to WT tau (R5L, ΔN296, V337M and E342V), while two of the 
mutants showed a clear decrease (L315R and K369I) (Figure 3.2A). 
 
LLS can be used as another method to measure relative amounts of protein aggregation (214).  
However, in this case the results differed from those found in ThS fluorescence.  Only three 
mutants showed a clear increase over WT (R5L, P301L and S352L), while five of the mutants 
showed a decrease in scattered light (G272V, G303V, L315R, S320F and K369I) and four 
mutants had levels similar to WT (ΔN296, V337M, E342V and G389R) (Figure 3.2B).  Results 
from one-way ANOVA analyses with Tukey’s multiple comparison tests can be found in Tables 
3.1 and 3.2.  This analysis demonstrates that not only are many of the mutants different from 
WT, but there is also a wide range in variation between mutants as well. 
 
3.4.3 FTDP-17 mutations induce varying effects on aggregate morphology 
Because LLS is known to be affected by the length distribution of the aggregates (214) and the 
structure of tau recognized by ThS is unknown (216, 239), the aggregates of tau were viewed 
directly by electron microscopy (Figure 3.3).  Direct visualization of the aggregates can help in 
elucidating some causes of the apparent variation between the ThS and LLS results (Figure 3.2).  
WT tau displays a characteristic mixture of longer filaments and smaller aggregates less than 100 
nm in length, hereafter described as oligomers (Figure 3.3A).  Examination of the images made it 
abundantly clear that the mutations were inducing very different effects on the aggregation of the 
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protein.  Some of the mutants, such as G303V and S320F are almost entirely made up of Figure 
3.2 
 
Figure 3.2. Polymerization of wild-type and FTDP-17 mutant tau measured by thioflavin S 
staining and right-angle laser light scattering.  Polymerization reactions contained 2 μM of 
WT or one of 12 FTDP-17 mutant versions of tau and 75 μM ARA.  Reactions were incubated 
overnight at 25° C.  The final extent of polymerization was measured by (A) ThS fluorescence 
and (B) right-angle LLS as described in the Experimental Procedures.  Data represent the mean 
from 3 experiments ±SD.  Stars represent p-value results from Student’s unpaired t tests 
comparing means from each mutant to WT.  (*), p < 0.05; (**), p < 0.01; (***), p < 0.001.  More 
extensive statistical analysis can be found in Tables 3.1 and 3.2. 
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Figure 3.3 
 
Figure 3.3. Electron micrographs of polymerization reactions containing 2 μM protein and 
75 μM ARA.  A representative electron micrograph for (A) WT tau, (B) R5L, (C) G272V, (D) 
ΔN296, (E) P301L, (F) G303V, (G) L315R, (H) S320F, (I) V337M, (J) E342V, (K) S352L, (L) 
K369I, and (M) G389R.  The scale bar in (M) represents 1 μm and is applicable for all images. 
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oligomers (Figures 3.3F and H).  Others, including R5L, S352L, and P301L seem to be lacking 
oligomers and display longer filaments than WT tau (Figures 3.3B, E, and K).  Very few 
aggregates were associated with K369I which confirms earlier ThS and LLS results (Figures 3.2 
and 3.3L).  I next sought to determine if the apparent observed differences could be detected by 
quantitative methods and whether these differences were significant.  To accomplish this I 
measured the number and length of filaments displayed in five representative images from each 
of three different reactions for each tau variant.    
 
Quantitation of the total amount of aggregated material indicated that most of mutant forms of 
tau variants polymerized to a similar extent as WT tau but images from G303V, S320F, and 
E342V all contained more total polymerized tau than WT (Figure 3.4A).  In contrast, K369I and 
G389R displayed less polymerization than WT in these images.  K369I had considerably fewer 
aggregates than WT and these aggregates were very short in nature and in general did not stain 
as intensely as tau aggregates associated with WT and the other mutants, again indicating low 
levels of polymerization (Figures 3.3L and 3.4B). 
 
The differences in aggregation, apparent in Figure 3.3, were confirmed by comparing the average 
lengths of all filaments for each tau variant.  Several mutants (G272V, G303V, L315R, S320F, 
and G389R) displayed shorter average filament lengths while filaments from R5L, P301L, and 
S352L were much longer on average than WT (Figure 3.4B).  Average filament lengths are not 
amenable to statistical analysis due to their exponential distribution.  Therefore, the data from 
each of the 15 electron micrographs were plotted as average filament length versus the number 
of filaments formed to demonstrate the variation in the data (Figure 3.5).  These plots also  
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Figure 3.4 
 
Figure 3.4. Quantitation of polymerized tau protein in electron micrographs.  Images in the electron 
micrographs from Figure 3 were quantified using Image-Pro Plus 6.0 as described in the Experimental 
Procedures.  The graphs display (A) the mean of the total length (μm) of polymerized tau 
filaments/image, (B) the mean length of filaments (nm), and (C) the percent of the total length coming 
from filaments less than 100 nm in length for each of the tau variants.  Data in (A) represent the mean of 
5 images from each of 3 separate reactions ±SD for a total of n=15.  Data in (B) represent the means of 
the mean filament length for each of the 15 images ±SD.  Data in (C) represent means of the sum of all 
filament lengths less than 100 nm as a percent of the total length for each image ±SD, n=15.  Stars 
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represent p-value results from Student’s unpaired t tests comparing means from each mutant to WT.  (*), 
p < 0.05; (**), p < 0.01; (***), p < 0.001. 
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Figure 3.5 
 
Figure 3.5. Average filament length vs filament number for all electron micrographs.  The 
quantitated values for average filament length and number of filaments per image are displayed 
here.  The values for each form of tau were grouped together to indicate differences and 
similarities among the aggregate morphologies in this assay.  The figure legend ranks each tau 
variant in order of average filament length and groups them based on the general trends of the 
mutation-induced effects on filament number and average filament length and how much these 
traces overlap with WT tau. 
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supported the differences in filament morphology described above.  Further variation can be 
observed by determining how much of the total polymerization is due to very short filaments.  I 
calculated the percent of the total polymerized material that was made up of filaments shorter 
than 100 nm (Figure 3.4C).  Around 30% of polymerized WT tau was contained in short 
filaments while oligomers made up greater than 90% of the total for G303V, S320F, and K369I.  
Others, such as R5L, ΔN296, P301L, and S352L, again induced a very different effect and 
contained much lower percentages, indicating that longer filament lengths and fewer oligomers 
were present (Figure 3.4C). 
 
In light of the quantitative EM data, the discrepancy between ThS fluorescence and LLS 
measurements of tau mutant aggregation is likely due to the disparate morphologies of the 
resulting filaments.  In fact, there is a direct correlation between filament length, as measured 
through electron microscopy (Figures 3.3 and 3.4B), and the ratio of ThS fluorescence to LLS 
values (Figure 3.6).  Therefore, the amount of light scattering from two populations of filaments 
of very different length distributions may not be equally proportional to the mass of filaments.  
 
3.4.4 Kinetics of polymerization varies by FTDP-17 mutant 
Because the morphology of tau aggregates can be influenced by the rate of polymerization (209), 
I sought to determine whether the mutations were affecting the kinetics of polymerization.  
Polymerization reactions for each mutant were followed by LLS and were then fit to a two-step 
model of polymerization to determine nucleation and elongation rates (Figure 3.7).  The K369I 
mutant had nearly undetectable levels of polymerization in this assay and could therefore not be 
fit to the model.   
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Figure 3.6 
 
Figure 3.6. Correlation between natural log of mean filament length and natural log of ThS 
to LLS ratio.  This plot displays correlation between the natural log of the mean filament length 
calculated from electron micrographs (Figure 3.4B) versus the natural log of the ratio of ThS 
values to LLS values (Figure 3.2).  This indicates that larger differences between ThS and LLS 
values are due to decreases in filament size.  The r
2
 value is 0.7339.  
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Figure 3.7 
 
Figure 3.7. Kinetics of tau polymerization. Polymerization reactions containing 2 μM tau were initiated 
by the addition of 75 μM ARA.  LLS readings were measured at specific time intervals until the reactions 
reached a steady-state.  The traces here represent mean values ±SD from 3 reactions fit to the Finke-
Watzky mechanism described in the Experimental Procedures and displayed over 250 minutes for WT tau 
protein (light gray) and various FTDP-17 mutant tau protein (black) including (A) R5L, (B) G272V, (C) 
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ΔN296, (D) P301L, (E) G303V, (F) L315R, (G) S320F, (H) V337M, (I) E342V, (J) S352L, and (K) 
G389R.  
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A visual inspection of the curves indicated a wide range of polymerization kinetics between 
mutants (Figure 3.7).  A comparison of nucleation rates (k1, Figure 3.8A) indicated that G272V, 
G303V, L315R, and S320F had significantly increased nucleation rates as compared to WT 
while R5L, P301L, E342V, and S352L had significantly decreased nucleation rates (Figure 
3.8A).  G303V, L315R and S320F also had greatly reduced elongation rates as compared to WT 
(k2, Figure 3.8B), such that the elongation phase was essentially undetectable.  E342V and 
S352L had elongation rates that were significantly reduced compared to WT but elongation was 
still detectable (Figure 3.8B).  The only mutant with a faster elongation rate than WT was P301L 
(Figure 3.8B).  In addition to these differences from WT protein, further analysis of the data 
using one-way ANOVA with Tukey’s multiple comparison tests demonstrates that many of the 
mutants are significantly different from one another.  For example, the kinetics of elongation 
(k2) of the P301L mutant is significantly different from G303V, L315R, S320F, V337M, S352L 
and G389R (Tables 3.3 and 3.4). 
 
3.4.5 FTDP-17 mutations can inhibit ability of tau to stabilize microtubule assembly or 
have little effect 
I then sought to determine whether the FTDP-17 mutations would have differential effects on 
one of tau’s normal functions of stabilizing microtubules.  Microtubule polymerization was 
monitored using a fluorescence based assay and the resulting curves (Figure 3.9) were fit to a 
Gompertz function in order to determine maximal extent of microtubule polymerization, the rate 
of elongation, and lag time in the presence of the FTDP-17 mutants (Figure 3.10).  Most proteins 
stabilized microtubules to similar levels as WT tau, but G303V, L315R, and S352L did not 
(Figure 3.10A).  P301L, G303V, S320F, and S352L induced microtubule elongation at a slower  
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Figure 3.8 
 
Figure 3.8. Comparison of tau polymerization kinetics. The parameters describing the tau 
polymerization kinetics curves fit to the Finke-Watzky mechanism are displayed.  The first 
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parameter is (A) k1, representing the rate of nucleation or formation of oligomers.  The second 
parameter is (B) k2, the rate of elongation or extension of the oligomeric tau aggregates into 
filaments.  Data represent means of values for fits of at least 3 separate reactions ±SD.  Stars 
represent p-value results from Student’s unpaired t tests comparing means from each mutant to 
WT.  (*), p < 0.05; (**), p < 0.01; (***), p < 0.001.  More extensive statistical analysis can be 
found in Tables 3.3 and 3.4. 
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Figure 3.9 
 
Figure 3.9. Microtubule assembly curves in the presence of tau.  Each point represents a mean value 
of the amount of tubulin polymerized into microtubules in the presence of wild-type tau (light gray) or tau 
with mutations of (A) R5L, (B) G272V, (C) ΔN296, (D) P301L, (E) G303V, (F) L315R, (G) S320F, (H) 
V337M, (I) E342V, (J) S352L, (K) G389R (black).  The values are fluorescence readings normalized to 
paclitaxel-stabilized polymerization of microtubules.  
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rate while V337M and E342V actually increased the rate of tubulin polymerization (Figure 
3.10B).  The lag time for tubulin polymerization was decreased in the presence of G272V, 
L315R, V337M, E342V, and G389R but increased in the presence of G303V and S352L (Figure 
3.10C).  In addition to these differences in FTDP-17 mutants as compared to WT, results from 
one-way ANOVA analyses with Tukey’s multiple comparison tests demonstrate that there were 
many statistically significant differences between FTDP-17 mutants as well (Tables 3.5-3.7). 
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Figure 3.10 
 
Figure 3.10. Stabilization of microtubule assembly by tau protein.  The tau variants were 
incubated with tubulin and its polymerization was measured via a fluorescence assay.  Numbers 
were normalized to values of polymerization in the presence of paclitaxel.  The relative 
fluorescence units (y-axis) were plotted vs. time (x-axis) and fit to the Gompertz equation as 
described in the Experimental Procedures.  From the parameters describing these curves, the 
percent of WT values for the (A) maximum amount of microtubule polymerization in presence 
of each protein, (B) kapp or rate of microtubule polymerization, and (C) lag time, the time before 
microtubule polymerization is detected.  The values in (A-C) are mean values of the percent 
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changes from WT in three separate experiments ±SD.  Stars represent p-value results from 
Student’s paired t tests comparing means from each mutant to WT.  (*), p < 0.05; (**), p < 0.01; 
(***), p < 0.001.  More extensive statistical analysis can be found in the Tables 3.5-3.7. 
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3.5 Discussion 
FTDP-17 mutations in tau are extremely rare but play a particularly important role in the study of 
tau aggregation associated with familial and sporadic tauopathies.  Some of these mutations are 
commonly used in disease models in order to enhance protein aggregation.  However, among the 
FTDP-17 mutants there exists significant variability in symptoms and pathology of diseases, 
indicating that there may be differing root causes of the disease.  While most known mutations 
are found within one of the four MTBRs, the locations vary from the N- to the C-terminal 
regions.  The amino acid substitutions or deletions result in increased or decreased 
hydrophobicity and charge, as well as induce a variety of potential changes in the transient 
secondary structure of the protein.  In addition, other factors such as alterations in splicing or 
phosphorylation pattern could be playing a major role in the neurodegenerative process. 
 
Because of the differences in pathology of aggregation and disease progression, it is important to 
determine how the mutations are changing the properties of the tau protein as well as how these 
changes could be affecting the associated neurodegeneration patterns.  Previous work has shown 
that the rate of tau aggregation into amyloid could be predicted by calculating expected changes 
in hydrophobicity, charge, and secondary structure due to three known FTDP-17 mutations 
(258).  In addition, other studies have examined the in vitro properties of small numbers of 
known mutants (214, 241, 244).  I sought to directly compare aggregation and function of WT 
and a wider variety of FTDP-17 mutant forms of tau under similar conditions, using the same 
mechanisms for inducing aggregation, as well as to determine whether these predictive tools 
would apply to an expanded field of mutations. 
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After studying the effects of FTDP-17 mutations on the in vitro aggregation of tau and its 
microtubule-stabilization properties I determined that the mutants had very distinct profiles from 
WT tau as well as each other.  I was able to group some of the mutants together based on their 
common properties and speculate on some of the causes for these general trends although I could 
not detect a clear pattern between the effects in these assays and the intrinsic changes predicted 
to occur due to mutations.  Some of the mutations induced similar effects on filament 
morphology that may be tied to their aggregation kinetics, but the overall trends pointed to large 
differences in the behavior of the mutated versions of tau in our assays. 
 
Several of the mutants displayed shorter average filament lengths than WT which seemed to be 
due to an increase in the number of oligomers and a decrease in the length and number of longer 
filaments.  The increase in the number of oligomers from this group may be explained by the 
increased rate of nucleation that was also associated with these four mutations.  Fast nucleation 
would take up large amounts of monomeric tau quickly and drop the protein level below the 
critical concentration of aggregation before elongation could begin.  Interestingly, four of the 
mutations with decreased filament length occur directly before and after the 
275
VQIINK and 
306
VQIVYK sequences, important for aggregation of tau, and may be causing increased 
nucleation through enhancements of the β-strand character (110, 261).  G272V, G303V, and 
S320F are predicted to enhance β-strand structure and extension of the β-strands in these regions 
has been shown to enhance polymerization in other mutants, although with slightly different 
effects (262).  The fourth mutation, L315R, is not predicted to enhance β-strand character, but it 
would replace a hydrophobic amino acid with a positive charge on the polar/charged side of an 
amphipathic β-strand which may help promote the cross-β amyloid structure (262).  
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Strengthening the β-strand secondary structure in these key regions may increase nucleation; 
making it more likely that tau will begin to aggregate, leaving little tau left for the elongation 
phase of polymerization.  Therefore the rate of nucleation is an important determinant of the ratio 
of oligomers to fibrils formed under these conditions. 
 
Another group of mutations induced the opposite effects on the filament morphology phenotype.  
R5L, P301L, and S352L all induced fewer, but longer filaments, than WT or the other mutant 
versions of tau.  These were slower to nucleate than WT tau which could be another indication of 
the importance of nucleation rate on filament morphology.  Despite the similarities in the rates of 
nucleation, the elongation rates of these three tau mutants varied widely compared to WT; R5L 
was similar, P301L was faster, and S352L was slower.  Even though each of these mutants 
aggregated into long filaments with few oligomers, the mechanisms of aggregation were quite 
dissimilar.   
 
It may seem unusual that R5L, a mutation that is far away from the MTBR, would have such 
large effects on the aggregation of the protein but the N-terminal region has been shown to have 
an enhancing effect on aggregation which may be due to alterations in the global hairpin 
conformation (54, 220, 229).  The P301L mutation is much closer to the 
306
VQIVYK  
hexapeptide than R5L and the removal of a proline in the PGGG sequence preceding it could 
assist in the formation of a β-strand in such a way as to stabilize the formation of longer 
filaments with an altered morphology (263).  S352L also enhances the β-strand character around 
the 
350
VQLKI sequence which is very similar to the 
275
VQIINK and 
306
VQIVYK sequences that 
100 
 
form the amphipathic β-strands crucial for the formation of tau filaments.  The addition of 
another amyloidogenic sequence could assist in stabilizing longer filaments. 
 
While the mutants discussed above had obvious effects on the morphology of the aggregates, 
other mutants, such as ΔN296, V337M, and E342V, displayed aggregates that were much more 
similar to WT protein. These mutants aggregated into mixes of short and long filaments with 
roughly the same number of filaments as WT tau.  These mutations are further from the 
275
VQIINK and 
306
VQIVYK sequences and may not have as strong of effects on those regions 
even if they are enhancing the β-strand character around them.  These minor changes may 
indicate that the root causes of these tauopathies may lie somewhere other than direct increases 
in tau aggregation.  For example, the N296 position is also associated with other FTDP-17 
mutations that can lead to splicing defects and V337M can lead to increased phosphorylation 
((182) and reviewed in (264)). 
 
While general trends in the aggregation of mutated proteins could be identified, the interactions 
with microtubules followed an alternate pattern.  Only mutations that occur within one of the 18 
amino acid repeats in the MTBR displayed effects on the ability of the protein to stabilize 
assembly of microtubules, confirming previous results with other FTDP-17 mutations (265).  Of 
the mutants that fell outside of the MTBR or in one of the interrepeats (R5L, L315R, V337M, 
E342V, K369I, and G389R) only L315R displayed any decrease from WT tau in the total 
amount of microtubule polymerization.  This was a relatively minor change compared to the 
effects of the other mutants and was in agreement with previous results (184).  All of the mutants 
located within one of the repeat regions were unable to stabilize the same maximum level of 
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microtubule polymerization, stabilized a slower rate of polymerization, or altered the lag time 
compared to WT tau.  These results, combined with the large percentage of FTDP-17 mutations 
located in a MTBR, indicate that interactions with microtubules may play a key role in the 
progression of these tauopathies.  Further research is needed to determine how altered 
microtubule interactions may be affecting tau aggregation as well as if affected microtubule 
dynamics may be playing a more direct role in toxicity.  
 
Direct comparisons of our results to previous studies can be difficult due to differing 
experimental setup.  The most common differences involve the type of tau aggregation inducer 
employed, the buffer conditions, and the tau isoform used in the assays.  Our data confirm 
previous results indicating that P301L is a very fast aggregator compared to WT, several of these 
FTDP-17 mutants have decreased abilities to stabilize assembly of microtubules and increased 
aggregation, and K369I typically forms smaller aggregates (214, 266-268).  Occasionally, 
differences were seen in the kinetics of aggregation that may be ascribed to how the data are 
measured and what type of curve they are fit to.  The Finke-Watzky mechanism appears to be 
best able to describe the complex process of tau aggregation in a simplified manner and 
accurately represented differences in the mechanisms of aggregation for the studied mutations. 
 
The fact that significant differences exist in how these mutants aggregate, the types of aggregates 
that are seen, as well as their ability to perform normal functions of tau in vitro should not be 
particularly surprising given the diversity in disease phenotype associated with FTDP-17 cases 
and tauopathies in general.  Conformational differences among the mutations are likely to affect 
the protein’s aggregation in complex ways which could then have a direct impact on disease 
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progression.  These differences could manifest themselves in the initiation, morphology, or 
spread of aggregation.  While the end result may always be aggregation of tau and degeneration 
of neurons, the mechanisms by which the various diseases reach that point may be drastically 
different and alternate therapeutic interventions may be required based on the initiating cause of 
the disorder.  As it is likely that sporadic tauopathies also differ in their initiating factors, 
information about how certain FTDP-17 mutations affect tau may be applicable to the 
progression of those diseases as well. 
 
In order to attempt to explain some of these initiating factors I attempted to find correlations 
between the intrinsic effects of our chosen mutations and their effects on tau in the various 
assays.  However, I was unable to detect any correlations among these components.  It is likely 
that these effects are complicated and dependent on the specific location of the mutation. 
 
Given the importance of the MTBR in the function and dysfunction of tau, it is likely that 
location is a very important factor for how these mutations are affecting the aggregation of the 
protein.  Mutations that increased the hydrophobicity and β-strand character, especially in the 
MTBR, seem to increase the rate of nucleation and decrease the average filament length but 
exceptions to this exist as well.  The causes of familial tauopathies are likely quite complex.  
Mutation-induced effects on intrinsic properties of tau may alter its propensity for aggregation or 
the morphology of its aggregates and lead to early-onset tauopathies.  However, changes in 
mRNA splicing, interactions with microtubules, or phosphorylation levels could also lead to 
aggregation of the protein or neuronal death.  In addition, the mutations could also affect other 
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properties of the protein including interactions with protein degradation systems, kinases, or fast 
axonal transport among others. 
 
Because of the variation in location and effects on intrinsic properties of tau, significant 
differences exist in how FTDP-17 mutations affect the protein.  While these mutations can be 
quite useful for in vitro and in vivo models of tau aggregation and tauopathies, it may be 
important to consider the differential effects when comparing results from various model 
systems.  Further work on characterizing these mutations and their effects on in vivo organisms 
may help explain how the various FTDP-17 mutations are leading to tauopathies and how these 
mechanisms are affecting our understanding of the progression of sporadic tauopathies. 
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Table 3.1.  One-way ANOVA analysis with Tukey’s multiple comparison test for ThS 
results.   
One-way ANOVA with Tukey's multiple comparison post 
test 
      ThS 
             
 
WT R5L 
G272
V 
ΔN29
6 
P301
L 
G303
V 
L315
R 
S320
F 
V337
M 
E342
V 
S352
L 
K369I 
G389
R 
WT x ns ns ns * ns ns ns ns ns *** *** ns 
R5L ns x ns ns ns ns ns ns ns ns ns *** ns 
G272V ns ns x ns ns ns * ns ns ns ns *** ns 
ΔN296 ns ns ns x *** * ns ** ns ns *** *** * 
P301L * ns ns *** x ns *** ns ns ** ns *** ns 
G303V ns ns ns * ns x ** ns ns ns ns *** ns 
L315R ns ns * ns *** ** x ** ns ns *** *** ** 
S320F ns ns ns ** ns ns ** x ns * ns *** ns 
V337M ns ns ns ns ns ns ns ns x ns ** *** ns 
E342V ns ns ns ns ** ns ns * ns x *** *** ns 
S352L *** ns ns *** ns ns *** ns ** *** x *** ns 
K369I *** *** *** *** *** *** *** *** *** *** *** x *** 
G389R ns ns ns * ns ns ** ns ns ns ns *** x 
 
ns – No statistically significant differences 
* P < 0.05 
** P < 0.01 
*** P < 0.001 
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Table 3.2.  One-way ANOVA analysis with Tukey’s multiple comparison test for LLS 
results.   
One-way ANOVA with Tukey's multiple comparison post test 
      LLS 
             
 
W
T 
R5
L 
G272
V 
ΔN29
6 
P301
L 
G303
V 
L315
R 
S320
F 
V337
M 
E342
V 
S352
L 
K369
I 
G389
R 
WT x ns ** ns ** *** *** *** ns ns *** *** ns 
R5L ns x *** * ns *** *** *** ns ns ns *** ** 
G272V ** *** x ns *** *** ns ** * * *** *** ns 
ΔN296 ns * ns x ** *** * *** ns ns *** *** ns 
P301L ** ns *** ** x *** *** *** ns * ns *** *** 
G303V *** *** *** *** *** x ** ns *** *** *** ns *** 
L315R *** *** ns * *** ** x * ** ** *** *** ns 
S320F *** *** ** *** *** ns * x *** *** *** ns *** 
V337
M 
ns ns * ns ns *** ** *** x ns * *** ns 
E342V ns ns * ns * *** ** *** ns x ** *** ns 
S352L *** ns *** *** ns *** *** *** * ** x *** *** 
K369I *** *** *** *** *** ns *** ns *** *** *** x *** 
G389R ns ** ns ns *** *** ns *** ns ns *** *** x 
 
ns – No statistically significant differences 
* P < 0.05 
** P < 0.01 
*** P < 0.001 
 
  
106 
 
Table 3.3.  One-way ANOVA analysis with Tukey’s multiple comparison test for tau 
polymerization nucleation, k1 rate constant, results.   
One-way ANOVA with Tukey's multiple comparison post 
test 
      
Kinetics k1 
           
 
WT 
R5
L 
G272
V 
ΔN29
6 
P301
L 
G303
V 
L315
R 
S320
F 
V337
M 
E342
V 
S352
L 
G389
R 
WT x ns ** ns ns *** *** *** ns ns ns ns 
R5L ns x ** ns ns *** *** *** ns ns ns ns 
G272V ** ** x ** *** *** *** *** ns *** ** ns 
ΔN296 ns ns ** x ns *** *** *** ns ns ns ns 
P301L ns ns *** ns x *** *** *** ns ns ns ns 
G303V *** *** *** *** *** x ns *** *** *** *** *** 
L315R *** *** *** *** *** ns x *** *** *** *** *** 
S320F *** *** *** *** *** *** *** x *** *** *** *** 
V337
M 
ns ns ns ns ns *** *** *** x ns ns ns 
E342V ns ns *** ns ns *** *** *** ns x ns ns 
S352L ns ns ** ns ns *** *** *** ns ns x ns 
G389R ns ns ns ns ns *** *** *** ns ns ns x 
 
ns – No statistically significant differences 
* P < 0.05 
** P < 0.01 
*** P < 0.001 
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Table 3.4.  One-way ANOVA analysis with Tukey’s multiple comparison test for tau 
polymerization elongation, k2 rate constant, results. 
One-way ANOVA with Tukey's multiple comparison post 
test 
      Kinetics k2 
           
 
W
T 
R5
L 
G272V ΔN296 P301L G303V 
L315
R 
S320
F 
V337
M 
E342
V 
S352
L 
G389
R 
WT x ns ns ns ns ** * * ns ns ns ns 
R5L ns x ns ns ns *** ** ** ns * * ns 
G272V ns ns x ns ns ns ns ns ns ns ns ns 
ΔN296 ns ns ns x ns ns ns ns ns ns ns ns 
P301L ns ns ns ns x *** *** *** * *** ** * 
G303V ** *** ns ns *** x ns ns ns ns ns ns 
L315R * ** ns ns *** ns x ns ns ns ns ns 
S320F * ** ns ns *** ns ns x ns ns ns ns 
V337M ns ns ns ns * ns ns ns x ns ns ns 
E342V ns * ns ns *** ns ns ns ns x ns ns 
S352L ns * ns ns ** ns ns ns ns ns x ns 
G389R ns ns ns ns * ns ns ns ns ns ns x 
 
ns – No statistically significant differences 
* P < 0.05 
** P < 0.01 
*** P < 0.001 
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Table 3.5.  One-way ANOVA analysis with Tukey’s multiple comparison test for results of 
total polymerization of microtubules.   
One-way ANOVA with Tukey's multiple comparison post test 
      
MT Polymerization Total 
          
 
WT 
R5
L 
G272
V 
ΔN29
6 
P301
L 
G303
V 
L315
R 
S320
F 
V337
M 
E342
V 
S352
L 
K369I 
G389
R 
WT x ns ns ns ns ns ns *** ns ns *** ns * 
R5L ns x ns ns ns * ns *** ns ns *** ns ns 
G272
V 
ns ns x ns ns *** ns *** ns ns *** ns ns 
ΔN296 ns ns ns x ns ns ns *** ns ns *** ns ** 
P301L ns ns ns ns x ns ns *** ns ns *** ns ** 
G303
V 
ns * *** ns ns x ** ** *** ** *** ns *** 
L315R ns ns ns ns ns ** x *** ns ns *** ns ns 
S320F *** *** *** *** *** ** *** x *** *** ns *** *** 
V337
M 
ns ns ns ns ns *** ns *** x ns *** ns ns 
E342V ns ns ns ns ns ** ns *** ns x *** ns ns 
S352L *** *** *** *** *** *** *** ns *** *** x *** *** 
K369I ns ns ns ns ns ns ns *** ns ns *** x * 
G389R * ns ns ** ** *** ns *** ns ns *** * x 
 
ns – No statistically significant differences 
* P < 0.05 
** P < 0.01 
*** P < 0.001 
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Table 3.6.  One-way ANOVA analysis with Tukey’s multiple comparison test for results of 
the rates of microtubule polymerization.   
One-way ANOVA with Tukey's multiple comparison post test 
      
MT Polymerization Rate, kapp 
          
 
WT 
R5
L 
G272
V 
ΔN29
6 
P301
L 
G303
V 
L315
R 
S320
F 
V337
M 
E342
V 
S352
L 
K369
I 
G389
R 
WT x ns ns ** *** *** ns *** *** * *** ns * 
R5L ns x ns *** *** *** * *** ns ns *** ns ns 
G272V ns ns x *** *** *** ns *** ns ns *** ns ns 
ΔN296 ** *** *** x ns ns * ns *** *** ns ** *** 
P301L *** *** *** ns x ns * ns *** *** ns *** *** 
G303V *** *** *** ns ns x ** ns *** *** ns *** *** 
L315R ns * ns * * ** x *** *** ** *** ns ** 
S320F *** *** *** ns ns ns *** x *** *** ns *** *** 
V337M *** ns ns *** *** *** *** *** x ns *** *** ns 
E342V * ns ns *** *** *** ** *** ns x *** * ns 
S352L *** *** *** ns ns ns *** ns *** *** x *** *** 
K369I ns ns ns ** *** *** ns *** *** * *** x ns 
G389R * ns ns *** *** *** ** *** ns ns *** ns x 
 
ns – No statistically significant differences 
* P < 0.05 
** P < 0.01 
*** P < 0.001 
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Table 3.7.  One-way ANOVA analysis with Tukey’s multiple comparison test for results of 
the lag times of microtubule polymerization.   
One-way ANOVA with Tukey's multiple comparison post test 
      
MT Polymerization Lag Time 
          
 
WT R5L 
G272
V 
ΔN29
6 
P301
L 
G303
V 
L315
R 
S320
F 
V337
M 
E342
V 
S352
L 
K369
I 
G389
R 
WT x ns ns ns ns ns ns *** ns ns *** ns * 
R5L ns x ns ns ns * ns *** ns ns *** ns ns 
G272V ns ns x ns ns *** ns *** ns ns *** ns ns 
ΔN296 ns ns ns x ns ns ns *** ns ns *** ns ** 
P301L ns ns ns ns x ns ns *** ns ns *** ns ** 
G303V ns * *** ns ns x ** ** *** ** *** ns *** 
L315R ns ns ns ns ns ** x *** ns ns *** ns ns 
S320F *** *** *** *** *** ** *** x *** *** ns *** *** 
V337M ns ns ns ns ns *** ns *** x ns *** ns ns 
E342V ns ns ns ns ns ** ns *** ns x *** ns ns 
S352L *** *** *** *** *** *** *** ns *** *** x *** *** 
K369I ns ns ns ns ns ns ns *** ns ns *** x * 
G389R * ns ns ** ** *** ns *** ns ns *** * x 
 
ns – No statistically significant differences 
* P < 0.05 
** P < 0.01 
*** P < 0.001 
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Chapter IV Generating and characterizing novel tauopathy models in C. elegans 
4.1 Abstract 
The mechanisms of aggregation and toxicity in tauopathies are not entirely understood but a 
variety of transgenic animal models have been developed to study these questions in an in vivo 
setting.  Data from Chapters II and II indicate that the choice of isoform background or FTDP-17 
mutation can directly and significantly impact the mechanisms of aggregation, aggregate 
morphology, and ability of the protein to perform its normal functions.  I set out to develop and 
characterize novel in vivo models of tauopathies in order to determine how some of the factors 
described earlier affect these models and to use the models to address how these factors affect 
disease pathologies.  Caenorhabditis elegans was selected as the model organism due to the ease 
of genetic manipulation and the relative simplicity of their nervous systems.  To begin, I 
generated several C. elegans lines that express various types of tau.  These included wild-type 
2N4R tau, a P301L FTDP-17 mutant, a 7-Phos pseudophosphorylation mutant, and 3PO, a 
modified version of tau optimized for aggregation.  Several of the resulting phenotypes were 
characterized for these lines in order to compare the effects of expressing various forms of tau.  
Worms expressing the types of tau associated with enhanced aggregation, P301L and 3PO, 
displayed decreased head-thrashing compared to worms expressing only GFP or wild-type tau.  
The lifespans of these worms appeared to be slightly decreased compared to worms expressing 
wild-type tau but not to a statistically significant degree.  These worms also displayed axonal 
defects that may be leading to neuronal dysfunction.  This demonstrates that C. elegans can be a 
useful system to analyze the differential effects of tau variants.  
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4.2 Introduction 
Biochemical techniques and assays can be very useful in determining how modifications of tau, 
such as phosphorylation or inherited mutations, affect the aggregation of the protein or how it 
interacts with microtubules.  While this can be very important, these techniques are unable to 
describe how those changes in aggregation and function affect neuronal dysfunction and death in 
a living organism.  However, this limitation can be overcome by applying results obtained from 
biochemical assays to make rational decisions when designing an animal model.  These could 
include using properties such as aggregate morphology or an altered ability to interact with 
microtubules to answer specific questions about how these properties affect toxicity.  For 
example, the results from Chapter III indicate that some FTDP-17 mutations induce the 
formation of very long filaments while others induce aggregates that remain in a primarily 
oligomeric state.  A transgenic worm line could be generated that expresses a form of tau 
associated with long filaments and another could be generated that expresses a form of tau 
associated with oligomeric aggregation.  A variety of physiological and morphological 
characteristics could then be used to compare the effects of expressing each type of tau.  
Differences in these phenotypes would likely be due to the differential effects induced by each 
specific aggregate-type.  In this manner, rational decision-making can be used to generate 
transgenic models that will allow us to isolate and compare the effects of specific traits 
associated with certain tau variants. 
 
Tauopathies have been modeled in many different organisms including mice, flies, nematodes, 
and fish (87, 197, 269, 270).  The model organism C. elegans was chosen for this study because 
it is relatively simple and inexpensive to generate multiple lines of transgenic animals making it 
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suitable for comparing the effects of various strains.  Previous versions of C. elegans tauopathy 
models have typically used one of the FTDP-17 mutations in order to enhance tau aggregation 
and exacerbate its negative effects.  One of the earliest models used V337M and P301L in the 
1N4R isoform (197).  The pan-neuronal expression of these tau variants induced a locomotion 
defect, known as “unc” for uncoordinated, that demonstrates neuronal defects within the worms.  
Degenerating neurons were confirmed by transmission electron microscopy.  Insoluble tau was 
associated with these neurons and could be isolated from worms expressing FTDP-17 tau (197).  
Another model used P301L or R406W expressed in the mechanosensory neurons (198). Again, 
the transgenic worms expressing mutant tau forms displayed more functional and morphological 
defects in their neurons than those expressing wild-type forms of tau (198).   
 
A more recent study utilized a truncated background, known as F3 and containing primarily 
MTBR regions, with a ΔK280 mutation as a pro-aggregant form.  An anti-aggregant form was 
generated by adding the I277/308P mutations (199).  The proline for isoleucine substitutions at 
those locations interrupts the β-strand character in the hexapeptide motifs that are so important 
for aggregation (271).  The nucleation rates of the tau fragments were slow until a full-length 
version of tau with the V337M mutation was added.  The combination of the F3ΔK280 fragment 
along with full-length V337M resulted in the formation of tau aggregates that were largely 
absent with the F3ΔK280-PP anti-aggregant form.  The ability to aggregate was closely 
associated with morphological defects in the neurons that occurred in the form of axonal gaps, 
pre-synaptic defects, and mislocalized mitochondria (199).  Interestingly, the addition of a 
known aggregation inhibitor reduced levels of insoluble tau and induced small reductions in the 
numbers of axonal gaps (199).   
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These models demonstrate that expression of tau in worms can result in protein aggregation and 
neuronal defects, two key aspects of tauopathies.  With this in mind I set out to examine how 
expression of some of the various forms of tau described in Chapters II and III affected worms 
and their neurons.  Some of the initial characterization and preliminary results from this study are 
presented here.  This is an entirely new undertaking for my group and was carried out with the 
assistance and guidance of Dr. Brian Ackley and his group.  The project is ongoing and will 
continue to expand but the first steps were designed to demonstrate that the models could be 
generated and that differential phenotypes could be detected that were simple to read and 
demonstrative of relative toxicity. 
 
Initially, transgenic models expressing one of four different forms of tau were generated at 
varying expression levels. This study included wild-type 2N4R tau, P301L tau, and 7-Phos tau 
along with an extremely pro-aggregant form of the protein known as 3PO tau.  This was treated 
as a positive control for aggregation and was originally optimized for that purpose by removing 
pattern breaking sequences in the first three potential MTBR with a purpose of enhancing β-
strand character and propensity for aggregation (272).  Based on previously published results 
3PO tau was supposed to aggregate very quickly and induce the most severe phenotypes.   
 
4.3 Experimental Procedures 
4.3.1 Generation of transgenic worms.  The C. elegans N2 strain was used for the 
microinjection and maintained at 20-22.5°C as described earlier (273).  All tau used was in the 
2N4R isoform background.  Wild-type tau (Prgef-1::tau::gfp), P301L tau (Prgef-
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1::tau(P301L)::gfp), pro-aggregant tau (Prgef-1::tau(3PO)::gfp), and 
pseudohyperphosphorylated tau (Prgef-1::tau(7-Phos)::gfp) were injected into the animals at 
varying concentrations including 0.5, 5, and 50 ng μl
-1
.  The Pstr-1 co-injection marker was 
injected at a concentration of around 5 ng μl
-1
. 
 
4.3.2 Motility assays. The motility of the worms was measured through a thrashing assay.  A 
single adult worm was placed in M9 buffer and the number of head thrashes/minute was counted.  
A head thrash was defined as a full movement from one side of the worm to the opposite side. 
 
4.3.3 Lifespan assays.  20 worms at the L4 stage were placed onto a plate.  They were counted 
after 24 hours, which was the “Day 0” time point.  The worms were counted every 24 or 48 
hours after that point until at least half of the worms had died. 
 
4.3.4 Imaging of neurons.  Z-stacks of the neurons were collected using an Olympus FV1000 
confocal microscope with multi-tracking parameters and a 60x Plan-apochromat objective.  
 
4.4 Results 
4.4.1 Motility defects associated with transgenic tau expression 
The transgenic expression of tau induced an assortment of behavioral defects in the worms.  One 
predominant example is the Unc, or uncoordinated, phenotype.  This is characterized by an 
abnormal and inhibited locomotion and coiling when stationary.  The severity of the phenotype 
was quantified by counting the head thrashes of worms suspended in M9 buffer.  Transgenic 
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worms expressing only GFP were used as a tau-negative control.  All of the worm lines 
expressing tau at injection concentrations of 5 ng/μL displayed impaired head thrashing ability 
compared to the GFP-control (Figure 4.1A).  The mean number of head thrashes per minute 
decreased by around 18 for worm lines expressing wild-type tau at an injection concentration of 
0.5 ng/μL when compared to GFP-only worms and around 12 for the worms expressing 7-Phos 
tau at the same concentration but these values were not considered significant according to an 
unpaired t-test (Figure 4.1B).  However, the motility of lines expressing P301L and 3PO tau 
variants were significantly inhibited (Figure 4.1B). 
 
4.4.2 Shorter lifespans for P301L and 3PO worms 
The lifespans of transgenic C. elegans expressing wild-type, P301L, and 3PO tau at 5 ng/μL 
were measured and were affected by the tau variant expressed.  The lifespans of P301L and 3PO 
worms were, on average, shorter than the wild-type tau worms (Figure 4.2).  As the P301L and 
3PO animals aged they became progressively less mobile, an event that appeared earlier than in 
the wild-type animals.  These worms began dying earlier than wild-type tau worms.  An average 
of 10% of these worms had died within 11 days of reaching adulthood while no wild-type tau 
worms died by that same time point.  The means of the median survival time for each trial were 
16.5 days for the wild-type tau worms, 15.25 days for the P301L worms, and 14.63 days for the 
3PO worms.   
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Figure 4.1 
ftd 
Figure 4.1. Head thrashes per minute for transgenic tau worms.  Worms were placed in M9 
buffer and the numbers of head thrashes were counted.  The mean number of thrashes per minute 
are displayed for transgenic worms expressing (A) GFP, wild-type 2N4R tau, P301L tau, and 
3PO tau with all tau lines previously injected at 5 ng μL
-1
 and (B) GFP, wild-type 2N4R tau, 
P301L tau, 3PO tau, and 7-Phos tau with all tau lines previous injected at 0.5 ng μL
-1
.  Error bars 
represent ±SD with an n≥15 for (A) and n≥8 for (B).  Stars represent p-value results from 
Student’s unpaired t tests comparing means from each strain.  (*), p < 0.05; (**), p < 0.01; (***), 
p < 0.001.   
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Figure 4.2 
 
Figure 4.2. Lifespan of transgenic tau worms.  This graph displays the percent of worms 
surviving a number of days after reaching adult the stage.  20 age-matched worms were counted 
from the time they reached adulthood until death.  Error bars represent ±SD with an n=3 for 
wild-type tau, n=2 for P301L tau, and n=4 for 3PO tau.  
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4.4.3 Axonal defects associated with P301L and 3PO tau 
Confocal microscopy images of individual neurons reveal that GFP-labeled wild-type tau is 
expressed throughout all neurons in the worms (Figure 4.3).    The tau appears to be filamentous, 
particularly in the axons.  Although this has not been confirmed, it is likely that the tau is binding  
to the microtubules and maintaining its function even in the worms.  The axons in tail ganglion 
appear to be normal in worms expressing wild-type tau (Figure 4.4A).  This stands in contrast to 
worms expressing P301L tau (Figure 4.4B).  These worms displayed kinked axons which is an 
indication of some type of defect.  These defects are consistent with the motility defects 
associated with the P301L strains (Figure 4.1).  The P301L tau appears to be more diffuse than 
the wild-type tau.  This pattern could be due to decreased interactions with microtubules and 
potentially indicative of some aggregation.  The aggregate-prone 3PO version of tau displayed 
very little labeling of axons (Figure 4.5).  In this version of tau the sequences associated with tau 
aggregation have been modified to remove pattern-breaking sequences that inhibit formation of 
the β-strands.  This may affect microtubule-binding but the enhanced β-strands lead to 
aggregation that can occur very quickly.  These aggregates may be apparent in the 
somatodendritic compartment. 
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Figure 4.3 
 
Figure 4.3 Expression of wild-type tau.  The expression of GFP-labeled wild-type tau under 
the Prgef-1 promoter is pan-neuronal.  The tau appears filamentous, especially throughout the 
axon.  This may indicate binding to microtubules.  Images generated by Brian Ackley. 
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Figure 4.4 
 
Figure 4.4 Axonal defects associated with P301L tau expression.  A) Tail ganglion in worms 
expressing GFP-tagged wild-type tau.  The axons appear similar to non-transgenic worms.  B) 
The same tail ganglion in worms expressing GFP-tagged P301L tau.  The axons appear kinked 
which is consistent with the reduced motility in these worms.  Images generated by Brian 
Ackley. 
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Figure 4.5 
 
Figure 4.5 Worms expressing GFP-tagged 3PO tau display aggregation and little labeling 
of axons.  The worms expressing the GFP-tagged 3PO tau lack the filamentous labeling on 
display in worms expressing wild-type and P301L tau variants.  This may indicate a lack of 
binding to microtubules.  The clumping in the cell body likely indicates an increase in tau 
aggregation compared to worms expressing the other forms of tau.  Image generated by Brian 
Ackley.  
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4.5 Discussion 
The results presented above demonstrate that transgenic expression of human tau can induce 
harmful effects on the neurons of C. elegans worms.  Expression of those types of tau that have 
been determined to be pro-aggregant forms, such as P301L and 3PO, typically displayed more 
severe phenotypes than wild-type tau and, in some cases the 7-Phos pseudophosphorylation 
mutants.  This suggests that tau aggregation is a likely cause of neuronal dysfunction in the 
worms.   
 
One indication of this neuronal dysfunction is the motility defects detected in the worms.  This 
type of motor defect is not seen in most human tauopathies but is associated with some, such as 
PSP (274).  The varying symptoms associated with human tauopathies are affected by which 
regions of the brain that are affected by the tau pathology.  The motor neurons of C. elegans can 
stand in as a model for human neurons with motor defects as an easily detectable phenotype for 
dysfunction.  The causes of this dysfunction should be elucidated in the future.  This will require 
characterization of the aggregates formed in these models in order to determine their similarity to 
the in vitro results from Chapters II and III.  Further imaging of the neurons will occur as well 
and strains of worms designed to test for pre- and post-synaptic dysfunction are being generated. 
 
Clear differences in the lifespans of the transgenic worms were not detected to a level of 
statistical significance but it did appear that some of the 3PO and P301L worms may begin dying 
earlier than those expressing wild-type tau (Figure 4.2).  This again suggests that pro-aggregant 
forms of tau are inducing more toxic effects on the worms that may be shortening their lifespans.  
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The 3PO and P301L worms appeared to be less mobile than wild-type worms as they aged and 
further characterization of exacerbated phenotypes in the aged worms may be necessary. 
 
The images of neurons expressing GFP-labeled tau seem to be consistent with the results from 
motility and lifespan assays.  The worms expressing wild-type tau do not seem to exhibit any 
axonal defects (Figure 4.4A).  The tau appears to be labeling microtubules in the axon as it 
would be expected to.  However, in more aggregate-prone versions of tau this labeling appears to 
be decreased (Figure 4.4B) or completely abolished (Figure 4.5).  C. elegans do not express 
endogenous tau but do express a protein with repeat regions similar to tau (275).  It is unlikely 
that decreases in the binding of transgenic tau to microtubules are inducing negative effects so 
the defects are likely related to aggregation of the protein.  Further studies will be needed to 
confirm insoluble tau levels in these worms.  The worms expressing 3PO tau did display highly 
concentrated areas expression that are likely to be aggregates.  These appear to be 
morphologically different than NFTs but further characterization will be required.  
 
The characterization of worms expressing these different forms of tau demonstrates that 
transgenic worms can be used to model certain simplified aspects of tauopathies.  The data from 
the motility assay indicate that neuronal dysfunction can be detected rather easily.  They seem 
consistent with previous demonstrations that aggregate-prone versions of tau are associated with 
greater dysfunction and toxicity.  In addition, the images of axonal defects and possible tau 
aggregation are consistent as well.  In the future, these same assays can be used to characterize 
differences that arise due to expression of other types of tau and in other isoforms, including 
those described in Chapters II and III.  The comparisons of the tau isoforms or various FTDP-17 
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mutations in an in vivo setting will give us the opportunity to take biochemical differences that 
are evident in our in vitro assays and determine what effects they might be having in a more 
physiological setting.  
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Chapter V 
Conclusions and Future Directions 
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Chapter V Conclusions and Future Directions 
5.1 Introduction 
Tauopathies, including AD, are among the greatest health challenges facing the United States 
and other industrialized nations.  While much progress has been made in treating and preventing 
other major causes of death, there are no effective treatments that can slow the progression of 
these diseases.  In fact, many important mechanisms of this disease progression have yet to be 
elucidated.  In order for effective treatments to be developed, a more complete understanding of 
the mechanisms of tau aggregation and toxicity will be needed.  This can be addressed by 
determining what factors initiate the aggregation of tau as well as elucidating the causes of 
varying pathologies that are associated with tauopathies in humans as well as in animal models 
of the diseases.  The studies described above attempted to address how specific modifications of 
tau affect its propensity to aggregate and perform its normal functions in order to learn about the 
initiation of tau aggregation and its resulting pathologies.  This information can then be applied 
to the design of in vivo experiments focused on answering questions about tau toxicity and 
disease progression. 
 
The most heavily studied post-translational modification of tau is its phosphorylation and many 
of the links between hyperphosphorylation and tau aggregation are widely characterized.  It may 
be the most important factor in initiating the aggregation of tau in sporadic tauopathies.  Prior to 
aggregation, tau seems to undergo conformational changes that result in an aggregate-prone form 
(55).  Changes in phosphorylation patterns seem to have the ability to affect the conformation of 
the tau protein in different manners (229).  Hyperphosphorylation, especially at specific sites, 
may be an initiator of this conformational change and lead to forms of the protein that are 
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particularly prone to aggregating.  However, similar phosphorylation patterns may not induce 
similar changes in conformation for all of the isoforms due to the presence or absence of certain 
exons.  While hyperphosphorylation of tau is seen in all tauopathies, the diseases can differ 
according to the tau isoform content found within the aggregates.  Specific phosphorylation 
markers can be identified with particular tauopathies which indicates that the phosphorylation 
pattern may be important in the development of that particular phenotype.  Differences between 
phosphorylation patterns may affect some tau isoforms differently than others and could induce 
differential propensities for aggregation.  Alterations in the aggregate morphology and isoform 
content found in various tauopathies may be due to conformational differences induced by 
certain combinations of phosphorylated residues.   
 
The FTDP-17 mutations are another modification of tau associated with conformational changes 
and protein aggregation.  These are autosomal dominant mutations that lead to very aggressive 
forms of frontotemporal dementia in which tau pathology occurs much earlier than that which is 
seen in sporadic tauopathies.  The pathologies associated with these mutations are varied but can 
resemble the pathologies of the more common sporadic tauopathies.  Determining the causes of 
these differences could lead to a better understanding of the progressions of other tauopathies.  
One of the most obvious differences occurs within the mutations themselves.  These mutations 
are located throughout the protein and induce a variety of intrinsic changes to the biochemical 
properties of tau.  Characterizing how these mutations affect the aggregation and function of tau 
allows us to directly compare them to each other and helps determine what factors may be 
particularly important for the initiation and propagation of tau aggregation and how these 
changes may manifest themselves in the final disease pathologies.  A better understanding of the 
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mechanisms underlying the progression of these diseases will allow for a more targeted approach 
to therapeutic intervention that will hopefully lead to more successful treatment outcomes. 
 
The results from our studies indicate that the effects of two important modifiers of tau can vary 
widely based on the isoform background or type of mutation.  Many previous in vitro and in vivo 
experiments focused on tau have been performed with a single isoform or with a single FTDP-17 
mutation.  Information gathered from these simplified studies has been and will continue to be 
very valuable.  However, when considering how tau is behaving in an actual disease it is prudent 
to understand that the effects may not be the same for every tau isoform.  Furthermore, the 
effects may also be different when all six isoforms are present or their ratios are altered due to 
changes in mRNA splicing.  Similarly, utilizing a particular FTDP-17 mutation in an in vivo 
model of tauopathy may not yield the same results as wild-type tau or another FTDP-17 mutated 
version. 
 
5.2 Phosphorylation and tau isoforms 
Hyperphosphorylation is one of the most common characteristics associated with aggregated tau 
in all tauopathies.  Most evidence suggests that hyperphosphorylation of tau is sufficient to 
induce aggregation of the protein although its role in an in vivo setting is a matter of some 
debate.  Hyperphosphorylation appears to modify the conformation of tau (229).  This has been 
postulated to be a tightening of the global hairpin conformation.  The tau isoforms display 
differences in the properties of their aggregation and it stands to reason that modifications that 
alter their conformation may be affected by the presence or absence of the alternatively spliced 
exons.  Given that some tauopathies are associated with preferential aggregation of certain types 
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of isoform it is possible that hyperphosphorylation and how it affects the isoforms may play a 
role in changing how tau aggregates in these diseases. 
 
Indeed, the results from Chapter II indicate that phosphorylation patterns do not necessarily have 
the same effects on the in vitro polymerization and microtubule interactions of the six tau 
isoforms.  Clear differences exist in how the six isoforms aggregate and interact with 
microtubules.  The most obvious factor affecting functional and dysfunctional differences 
between isoforms is the presence or absence of exon 10.  This exon contains the 1-2 interrepeat 
region, including the 
275
VQIINK sequence involved in tau-tau interactions, and the repeat region 
of the 2nd MTBR.  The 4R tau isoforms aggregate quicker and to a larger degree as well as are 
better able to stabilize the assembly of microtubules than their corresponding 3R isoforms 
(Figures 2.2, 2.4, and 2.10).  The kinetics of aggregation (Figure 2.9) indicate that the 
mechanisms involved can vary according to isoform type as well.  The 7-Phos modifications 
seemed to enhance tau aggregation in the 4R isoforms while seeming to inhibit aggregation of 
the 3R isoforms in the assays. 
 
In AD and some other tauopathies, all isoforms are included in the aggregates in roughly the 
same proportions as found in the normal brain while the aggregates from other tauopathies are 
primarily made up of 3R or 4R isoforms.  The demonstration that a similar phosphorylation 
pattern can enhance or inhibit tau aggregation depending on the isoform type can have 
significant implications for the initiation of tauopathies.  For example, it could help describe how 
differential aggregation of the tau isoforms arises in some tauopathies but not in others.  It is 
possible that hyperphosphorylation could occur in different patterns based on the expression 
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levels of various kinases in certain cell-types or regions of the brain.  Specific phosphorylation 
patterns may enhance aggregation of 4R isoforms while inhibiting aggregation of 3R isoforms or 
vice versa. 
 
Pseudophosphorylation also induced isoform-specific inhibitory effects on the protein’s ability to 
stabilize assembly of microtubules (Figure 2.10).  Changes in the tau isoform ratio can affect the 
stability of microtubules and are also associated with early-onset forms of tauopathy (276).  The 
isoform-specific alterations in function due to hyperphosphorylation demonstrated here could be 
playing a role in disease initiation by changing the dynamics of microtubules or increasing the 
concentrations of cytosolic tau. 
 
The evidence from this study clearly suggests that a similar phosphorylation pattern can induce 
very different effects on the propensity of each isoform to aggregate or stabilize microtubule 
assembly in our assays (Figures 2.6, 2.7, and 2.10).  The SDS-resistant, but urea-sensitive, 
electrophoretic shift associated with the 7-Phos mutation (Figure 2.1C) provides evidence that 
the changes induced by pseudophosphorylation are conformational in nature.  The differences in 
magnitude suggest that these changes are unique for each the isoforms.  Previous work with 
fluorescence resonance energy transfer (FRET) demonstrated that pseudophosphorylation 
mutations, similar to the ones generated in this study, tightened the global hairpin conformation 
for 2N4R tau and resulted in a conformation recognized by antibodies that detect pathological 
tau (229).  The highly flexible nature of tau and the margin of error inherent in the FRET 
analysis prevent a detailed understanding of the structural characteristics of tau but general 
conclusions can be drawn.  The results from this study indicate that identical phosphorylation 
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patterns can affect isoforms differently and strongly suggest that this is due to isoform-specific 
conformational differences.  Similar FRET experiments could be utilized to help confirm this 
and determine specific information about how the 7-Phos pseudophosphorylation mutations are 
affecting the conformation of the other five isoforms. 
 
5.3 FTDP-17 mutations 
The disease phenotypes and pathologies associated with FTDP-17 mutations can vary as widely 
as those associated with the entire range of sporadic tauopathies.  For example, tau aggregates 
are deposited in different regions on the brain and still typically associate with 
neurodegeneration in the same regions.  These aggregates can appear very different from each 
other.  Straight or helical filaments are formed in some cases while tau fibrils are virtually 
nonexistent in others.  Larger inclusions can resemble NFTs, typically seen in AD, while others 
are more like Pick bodies or globose tangles.  The results from in vitro assays described in 
Chapter III clearly indicate that the specific mutation can have dramatic effects on the 
morphology of tau aggregates that are formed.  These differences are likely to influence the 
progression of human tauopathies and may alter results from animal models of the diseases.  
 
In FTDP-17-related disorders, isoform expression in the brain can remain normal or vary.  In a 
similar manner, the aggregates associated with the diseases can be made up of all isoforms or 
only a particular subset of isoforms even when expression levels of the isoforms have not 
changed.  The age of onset for the familial forms of diseases varies but is typically much earlier 
than that of sporadic tauopathies.  This early age of onset indicates that the initiation of the 
disease process likely begins earlier than it does for sporadic tauopathies or the diseases progress 
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much more rapidly once they are initiated.  Many of the FTDP-17 forms of tau aggregate much 
more readily compared to wild-type protein, a property that makes them very useful for 
transgenic animal models.  Despite their uses in animal models, not all FTDP-17 mutations may 
accurately reflect mechanisms associated with sporadic tauopathies and could, in fact, be very 
different from other FTDP-17 mutations.  The differences between the various FTDP-17 
disorders may tell us a lot about how other tauopathies are initiated.  Early-onset tauopathies may 
arise due to enhanced aggregation propensity through direct means, such as alteration of tau 
conformation, or indirect means, such as increased phosphorylation levels.  It may also involve 
altered mRNA splicing levels or increased soluble levels of tau through inhibited interactions 
with microtubules.  By learning more about the initiation of FTDP-17-related tauopathies we can 
also learn more about the more common sporadic tauopathies. 
 
This set of experiments was designed to characterize the in vitro aggregation and function of a 
group of FTDP-17 tau mutants in order to identify differences in how the mutations affected 
these properties.  Based on this information we can begin to determine the role these mutations 
play in initiating tauopathies and how they may lead to such varying pathologies.  The results 
from these assays demonstrated that the mutants displayed very different profiles in their 
aggregation and ability to stabilize microtubules.  This supports the hypothesis that initiation of 
these diseases can occur due to a variety of factors.   
 
The most obvious differences between FTDP-17 mutations were displayed in the morphologies 
of the filaments that were formed in the presence of ARA (Figure 3.3).  Several of the mutants 
formed very few filaments longer than 50 nm while others formed filaments that were much 
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longer than those formed from wild-type tau.  This demonstrates that changes to a single amino 
acid can greatly enhance or inhibit the propensity for aggregation.  Because all mutations do not 
enhance aggregation it is likely that this is not the sole cause of these diseases or their early-onset 
compared to sporadic tauopathies.  Inhibition of the interactions with microtubules may also play 
a role by increasing the concentration of unbound tau to levels where nucleation of aggregation 
may occur.  Our assay demonstrated that the effects of the mutants on the abilities to stabilize 
microtubule polymerization were variable when compared to each other (Figure 3.9).  
Alterations in splicing ratios may affect the concentrations of unbound tau as well as changing 
the microtubule dynamics.  Effects such as these would not show up in the chosen assays but 
may be an initiating factor for some of the mutants, particularly those with profiles that appear 
similar to wild-type tau. 
 
Like the 7-Phos pseudophosphorylation modifications, FTDP-17 mutations are likely affecting 
the conformation of the tau protein which induces the related effects on aggregation and 
microtubule interactions.  However, unlike the hyperphosphorylation, these changes are likely to 
involve more direct effects on the local secondary structure.  For example, enhancing the β-
strand structure at a key location may greatly affect the likelihood that the protein maintains that 
structure long enough for the monomer to interact with another tau molecule.  Certain sites are so 
common among the known FTDP-17 mutations that it is probable they have a key role 
somewhere in the process.  For example, as part of every MTBR there is a PGGG sequence that 
may be involved in forming loops when binding to microtubules (23).  Over a third of the known 
FTDP-17 mutations (Table 1.1) are located within one of the four PGGG sequences found in tau.  
Additionally, four more mutations are located at one of the two amino acid residues directly 
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downstream from these sequences meaning nearly half of all known FTDP-17 mutations reside 
in or next to one of these sequences (Figure 5.1).  The PGGG sequence is highly flexible and 
may be present, in part, to break up the β-strand character of the sequences that lie just 
downstream.  These sequences appear in the MTBR and may have an important function in the 
interactions with microtubules.  However, due to some of these mutations, the β-strand character 
in these critical regions is likely enhanced and leading to increases in aggregation.  The 
propensity for β-strand structure is a key factor in the aggregation of tau and the presence of 
longer β-strands or increased likelihood of forming this secondary structure could alter the 
kinetics of aggregation.  Enhanced aggregation is a likely cause of the early-onset for many of 
these FTDP-17 related dementias.  However, this raises the question of how the different 
morphologies of aggregates formed from the FTDP-17 mutants in our assays are affecting 
disease. 
 
The pathologies of the various FTDP-17 diseases are similar yet also dissimilar in many ways.  
The end result is usually large inclusions of tau but these inclusions can vary morphologically, 
by isoform content, and type of fibril.  The results of our assays demonstrate morphological 
differences in the type of aggregates formed by the various forms of tau.  The tau aggregation is 
in a setting that is designed to promote aggregation through the addition of inducer molecules.  
In a disease setting the aggregation of tau takes place over the course of many years.  The prion-
like model of tau aggregate propagation would predict that a conformational change occurs in tau 
that is found in a relatively small region of the brain.  As this conformationally-distinct form of 
tau aggregates it can also induce similar conformational changes in tau in neighboring regions of 
the brain.  It stands to reason that the presence of mutated tau that may already be predisposed to  
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Figure 5.1 
 
Figure 5.1 FTDP-17 mutations clustered in microtubule-binding repeat regions.  Many of 
the FTDP-17 mutation sites (residues shown in gray) are located in the MTBR.  Nearly half of all 
known mutations are located in or just downstream from one of the PGGG sequences. 
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exist in an altered conformation would allow for faster propagation and an earlier onset of 
disease.  Even with FTDP-17 tau, the earliest onset of frontotemporal dementias does not 
typically occur for 2 to 3 decades.  Over this long period of time it is likely that aggregates are 
joining together in order to form longer fibrils and larger inclusions.  Mutants like G303V or 
S320F that typically did not form long filaments in our in vitro assays may still form larger tau 
aggregates over the course of many years.  However, an increased propensity for aggregation 
that results in formation of small oligomers may instead lead to more aggressive propagation of 
the tau pathology.  Further studies of these mutant forms of tau in an in vivo neuronal setting 
may answer some of these questions. 
 
Additionally, alterations in the splicing ratio associated with some of these FTDP-17 mutations 
are likely to play a huge role in how they induce tauopathies but is not something that was 
addressed by this particular study.  Of the mutations studied above, G303V and E342V are 
associated with increased inclusion of exon 10 while alterations in splicing ratios have not been 
found or have not been examined for the others.  Despite the lack of changes in isoform splicing, 
differential isoform inclusion in aggregates are associated with several of the mutations.  This 
typically takes the form of increased aggregation of 4R isoforms compared to 3R tau for this 
group of mutation.  Further study into isoform-specific effects, such as those presented in chapter 
II, may help explain some of the causes behind this selective aggregation. 
 
The negative effects of these mutations are also not likely to be entirely related to aggregation.  
Other FTDP-17 mutations may be inducing toxicity partially through altered microtubule 
dynamics.  Some of the mutants were able to stabilize microtubule polymerization at a faster rate 
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than wild-type.  In the context of a human neuron, enhancing polymerization of microtubules 
could be just as likely to induce harmful effects as an inhibited ability to stabilize the 
polymerization.      
 
5.4 Conformation as destiny? 
The evidence presented in the chapters above clearly indicates that relatively minor 
modifications of tau can induce large effects on the protein’s aggregation and function.  These 
modifications can be very small, such as a single amino acid substitution in the FTDP-17 
mutations, or they can be larger, such as the effects of phosphorylation at multiple sites 
throughout the protein.  The changes can also have very different effects depending on the 
isoform background.  The electrophoretic shifts associated with the 7-Phos mutations were 
different for all of the six tau isoforms, likely because the amount of hairpin compaction was 
different for each of the isoforms (Figure 2.1).  The extremely flexible nature of tau makes it 
extraordinary difficult to determine much information about the state of its secondary structure 
or global conformation.  It is difficult to draw too many specific conclusions about the nature of 
the conformational change but the evidence seems to suggest that alterations to certain regions of 
secondary structure or the global hairpin conformation are affecting the kinetics of aggregation, 
the morphology of the aggregates, and its ability to interact with microtubules. 
 
If tau aggregation is propagated through a prion-like manner of inducing conformational changes 
in other tau monomers then the specifics of these changes could be important.  Conformational 
changes have been demonstrated to have a direct effect on aggregate morphology and disease 
phenotype for other proteins associated with aggregation diseases (277-279).  Altered 
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conformation of individual tau monomers could be the key factor leading to different fibril 
morphologies, tau isoform inclusion, and disease progressions (8, 172, 219).  It is possible that 
different “strains” of tau conformations may not respond to treatments that are designed to block 
tau aggregation.  This may have to be considered when designing and testing these potential 
therapeutics. 
 
According to the results described in Chapter II, a similar phosphorylation pattern has very 
different effects on 3R isoforms than it does on 4R isoforms.  Attempts to regulate the 
phosphorylation levels of tau have been proposed as a potential treatment for these diseases 
(reviewed in (280)).  This may still be an effective strategy for preventing aggregation or the 
buildup of toxic hyperphosphorylated soluble forms of the protein but the same strategies may 
not work for some of the tauopathies displaying isoform-specific aggregation that is being 
affected by phosphorylation. 
 
5.5 C. elegans models 
The current C. elegans models of tauopathy indicate that worms expressing the tau variants 
associated with aggregation appear to develop more severe phenotypes.  They are less motile and 
display axonal dysfunction which supports the idea that tau aggregation is inducing these defects.  
The work that has been accomplished so far indicates that they can be used as an in vivo 
experimental system to use in conjunction with our in vitro assays.  In this way, information that 
is learned from the biochemical assays can be used to design in vivo assays that answer questions 
about the toxic effects of tau aggregation.  Differences in motility can indicate more dysfunction 
and microscopy techniques can directly visualize defects in neurons. 
141 
 
 
Additionally, the phenotypic differences between the strains of worms indicate that the type of 
tau expressed in animals can induce varied effects.  This may have implications for the design of 
other animal models as well but further study with more altered forms of tau will be needed and 
are currently ongoing. 
 
5.6 Future Directions 
As mentioned in Chapter IV, the projects described here are ongoing and the next steps will 
primarily focus on continuing and expanding the C. elegans experiments.  The initial 
characterization of the worms expressing wild-type, P301L, 7-Phos, and 3PO tau will continue in 
order to establish baselines for the motility and lifespan assays described earlier.  In addition, 
more assays will be tested in order to determine if can be used to characterize relative levels of 
dysfunctions among the different strains.  This will allow direct comparison of future C. elegans 
strains to the four established strains.  Essentially, worms expressing 3PO tau are acting 
something like a positive control with very aggressive tau aggregation and severe phenotypes.  
On the other end of the scale, wild-type tau or I277/308P (incompetent for aggregation) will act 
as a negative control due to its minimal tau aggregation resulting in less severe phenotypes.  
There are many potential assays that can serve as readouts for neuronal dysfunction in these 
animals.  Neuronal defects often lead to the Unc phenotype, described in Chapter IV, and other 
motility assays can detect the severity of the phenotype.  The head thrashing assay is one 
example that has already been utilized (Figure 4.1).  Examples of future assays include 
determining the average velocity of the worms as well as counting the percent that are able to 
successfully reverse direction when they detect an anterior touch stimulus.  As the worms age 
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these motility defects appear to worsen for worms with the pro-aggregant forms of tau (P301L 
and 3PO) which means that a more profound effect may be seen with older worms than those 
that have just reached adulthood.  Experiments that measure the phenotype of aged worms could 
provide a clearer expression of dysfunction. 
 
While these assays can give a quick indication of relative dysfunction among the various lines, 
further analysis will also be needed.  It may be beneficial to determine how these various forms 
of tau are affecting the neuronal projections of the worms.  Axonal dysfunction can be examined 
through confocal microscopy due to the GFP-labeling of the tau constructs.  Additionally, 
recently generated strains are in backgrounds that contain pre- and post-synaptic markers that 
will allow us to determine the effects that these various tau variants have on synaptic 
dysfunction, a problem in AD that may be linked to tau or Aβ oligomer accumulation (281, 282).  
Determining the types of aggregates that are present in the worms will help establish the effects 
that oligomers or larger fibrils can have on synapse function.  
 
A characterization of insoluble tau will also indicate to what extent the tau variants described in 
Chapters II and III may contribute to future studies examining the relative toxicities of NFTs and 
oligomers.  One of the major goals of this study was to utilize the in vitro assays for tau 
aggregation and microtubule stabilization to generate a profile of each of the modified versions 
of tau in order to apply that information to in vivo studies about their behavior in neurons and 
disease progression.  Confirmation of the filament morphology will be an important initial step 
and can be performed with in situ oligomer specific antibodies or purification of insoluble tau 
followed by transmission electron microscopy.  The purification of tau will also allow a 
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determination of total and insoluble levels of the protein for the various strains of worms.  This 
will serve the purpose of validating that expression levels are similar for each of the strains as 
well as confirming the propensity for aggregation of each of the tau variants. 
 
Following the characterization of the first group of worms, more lines will be generated.  These 
should include several of the other FTDP-17 mutants and will include mutants that represent a 
cross-section of aggregate lengths and abilities to stabilize microtubule assembly.  The DNA 
constructs of some of these have been completed while others are in the process of being 
generated at the current time.  After they are generated, the new C. elegans strains can be 
characterized in the same manner as the original group described above. 
 
After the completion of the characterization of several C. elegans lines it would be useful to 
express some of the same variants of tau in cell culture or other model organisms.  This would 
allow comparisons across model systems.  Similar results would bolster the argument that there 
are intrinsic differences between the tau isoforms or the FTDP-17 mutations that directly affect 
phenotypes in a predictable manner.  If the results are dissimilar it would support the idea that 
organism-specific factors are altering the behavior of tau in other ways. 
 
In addition to strains that express tau variants in all of their neurons, strains that restrict the 
expression to GABAergic or cholinergic neurons have already been generated and are being 
characterized.  Certain collections of cholinergic neurons may be particularly vulnerable in AD 
and loss of these neurons can lead to some of the common cognitive impairments associated with 
the disease (283, 284).  However, more recent evidence suggests that these neurons are not 
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affected until later in the disease (285, 286).  According to some animals models it may, in fact, 
be the GABAergic neurons that are selectively targeted and the cause of this cognitive 
impairment but this is relatively untested (287).  Both types of neurons innervate the 
hippocampus from the basal forebrain and may play key roles in promoting the memory loss and 
other deficiencies associated with AD.  By testing the effects of limiting tau overexpression to 
these two types of neurons we hope to address some of the questions surrounding potential 
selective vulnerability by determining if tau expression has neuronal transmitter-specific effects 
in the worms. 
 
In addition to the future work with animal models there are in vitro biochemical experiments that 
can be performed as well.  One potential example would be to study some of the effects of the 
FTDP-17 mutations on the other five tau isoforms.  Given the results in Chapter II it is clear that 
modifications, such as phosophorylation, can induce isoform-specific effects on aggregation and 
function that can be quite varying when compared to other isoforms.  The missing exons may be 
altering any conformational changes due to the modifications.  This same effect would likely 
happen with mutation-induced alterations.  FTDP-17 mutations have several other specific links 
to tau isoforms that make this a particularly intriguing matter to study.  Several of the mutations 
are associated with altered splicing ratios that increase or decrease the 4R:3R tau ratio.  Even 
some mutations that do not affect mRNA splicing have been associated with preferential 
aggregation of specific isoforms, similar to that which is seen with several of the sporadic 
tauopathies discussed in Chapter I.  Finally, several of the mutations are found in exon 10 which 
would make them absent from the 3R isoforms altogether.  The vast majority of the mutations 
are located in the MTBR and the absence of this exon may alter the overall effects of a particular 
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mutation.  Studies using rationally chosen FTDP-17 mutations in the various isoforms could help 
explain some of the differential aggregation by demonstrating the types of effects that may alter 
one isoform type but leave another unaffected.  This information may be applicable to sporadic 
tauopathies that display differential aggregation such as progressive supranuclear palsy or Pick’s 
disease. 
 
The results described above indicate that many of the factors surrounding the initiation and 
propagation of tau aggregation are quite complex.  Hyperphosphorylation may induce 
conformational changes in tau that increase its propensity to aggregate but the changes and their 
effects may be very different depending on which isoform of tau has been phosphorylated.  In 
humans, FTDP-17 tau mutations can lead to the onset of tauopathies at a much younger age but 
the mutations may be initiating the disease in different manners.  These could include direct or 
indirect methods of increasing aggregation or through decreased binding to microtubules.  
Additionally, the type of mutation was able to alter the morphology of the aggregates that are 
formed as well as its ability to carry out normal functions.   
 
All of this implies that hyperphosphorylation and FTDP-17 mutations may induce 
conformational changes that affect the behavior of tau in these assays as well as in the afflicted 
brains.  These conformational differences may be a key determinant in the pathologies associated 
with the different tauopathies.  In addition, it may be challenging to directly compare results 
from animal models that utilize varying methods to induce tau aggregation.  The studies 
described here show that the use of in vitro assays can allow us to determine how modifications 
of tau may be altering key factors associated with tauopathies, which is information that can then 
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be used to further analyze their effects in an in vivo setting.  Through continuation of these 
studies we can begin to gain a clearer understanding of the mechanisms of tau toxicity in 
Alzheimer’s disease and other tauopathies which will hopefully lead to advances in treatments of 
these disorders.  
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